

## V. BIBLIOGRAFÍA



## A

Adibi SA. Metabolism of branched-chain amino acids in altered nutrition. *Metabolism*. 25: 1287-302 (1976)

Adigun AQ, Ajayi AA. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. *Eur J Heart Fail*. 3:359-63 (2001)

Agah R, Malloy B, Sherrod A, Bean P, Girgis E, Mazumder A. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor. *J. Biol. Response Mod*. 7: 140-51 (1988)

Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. *Thorax*. 59:483-7 (2004)

Ahlberg J, Berkenstam A, Henell F, Glaumann H. Degradation of short and long lived proteins in isolated liver lysosomes. *J. Biol. Chem*. 260: 5847-54 (1985)

Allen DL, Sartorius CA, Sycuro LK, Leinwand LA. Different pathways regulate expression of the skeletal myosin heavy chain genes. *J Biol Chem* 276: 43524-43533, (2001)

Andreucci JJ, Grant D, Cox DM, Tomc LK, Prywes R, Goldhamer DJ, Rodrigues N, Bedard PA, McDermott JC. Composition and function of AP-1 transcription complexes during muscle cell differentiation. *J Biol Chem*. 277:16426-32 (2002)

Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochim Biophys Acta*. 1072:129-57 (1991)

Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. *Lancet*. 361:1077-83 (2003)

Anti M, Marra G, Armelao F, Bartoli GM, Ficarelli R, Percesepe A, De Vitis I, Maria G, Sofo L, Rapaccini GL, et al. Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. *Gastroenterology*. 103:883-91 (1992)

Antinozzi PA, Berman HK, O'Doherty RM, Newgard CB. Metabolic engineering with recombinant adenoviruses. *Annu Rev Nutr*. 19:511-44 (1999)

Arbós J, López-Soriano FJ, Carbó N, Argilés JM. Effects of tumour necrosis factor- $\alpha$  (cachectin) on glucose metabolism in the rat. Intestinal absorption and isolated enterocyte metabolism. *Mol. Cell. Biochem*. 112: 53-9 (1992)

Argilés JM and Azcón-Bieto J. The metabolic environment of cancer. *Biol. Cell. Biochem*. 81: 3-17 (1988)

Argilés JM and López-Soriano FJ. Catabolic proinflammatory cytokines. *Curr. Opin. Clin. Nutr. Metab. Care*. 1: 245-51 (1998)

Argilés JM and López-Soriano FJ. The enzymatic activities of branched-chain amino acid catabolism in tumour-bearing rats. *Cancer Lett*. 61: 239-42 (1992)

Argilés JM and López-Soriano FJ. The oxidation of leucine in tumour-bearing rats. *Biochem. J*. 268: 241-4 (1990a)

Argilés JM and López-Soriano FJ. The role of cytokines in cancer cachexia. *Med. Res. Rev*. 19: 223-48 (1999)

Argilés JM and López-Soriano FJ. Why do cancer cells have such a high glycolytic rate? *Med. Hypoth*. 32: 151-5 (1990b)

Argilés JM, Alvarez B, López-Soriano FJ. The metabolic basis of cancer cachexia. *Med. Res. Rev*. 17: 477-98 (1997)

Argiles JM, Busquets S, Lopez-Soriano FJ. The role of uncoupling proteins in pathophysiological states. *Biochem Biophys Res Commun*. 293:1145-52 (2002).

Argilés JM, García-Martínez C, Llovera M, López-Soriano FJ. The role of cytokines in muscle wasting: its relation with cancer cachexia. *Med. Res. Rev.* 12: 637-652 (1992)

Argilés JM, López-Soriano FJ, Pallarés-Trujillo. Ubiquitin and Disease. Molecular Biology Intelligence Unit. Landes Company. Austin, Texas, USA. (1998)

Argilés JM, López-Soriano FJ, Evans RD, Williamson DH. Interleukin-1 and lipid metabolism in the rat. *Biochem. J.* 259: 673-678 (1989a)

Argilés JM, López-Soriano FJ, Wiggins D, Williamson DH. Comparative effects of tumour necrosis factor- $\alpha$  (cachectin), interleukin-1 $\beta$ , and tumour growth on amino acid metabolism in the rat in vivo. Absorption and tissue uptake of  $\alpha$ -amino[1- $^{14}$ C] isobutyrate. *Biochem. J.* 261: 357-62 (1989b)

Argilés JM, López-Soriano FJ. The energy state of tumor-bearing rats. *J. Biol. Chem.* 266: 2978-2982 (1991)

Argilés JM, López-Soriano J, Busquets S, López-Soriano FJ. Journey from cachexia to obesity by TNF. *FASEB J.* 11:743-51. (1997)

Argilés JM, Meijsing SH, Pallarés-Trujillo J, Guirao X, López-Soriano FJ. Cancer cachexia: A therapeutic approach. *Med Res Rev.* 21: 83-101 (2001)

## B

Bachmair A, Finley D and Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. *Science.* 234: 179-86 (1986)

Baeuerle PA, Baltimore D. NF-kappa B: ten years after. *Cell.* 87:13-20 (1996)

Bagby GJ, Lang CH, Hargrove DM, Thompson JJ, Wilson LA and Spitzer JJ. Glucose kinetics in rats infused with endotoxin-induced monokines or tumor necrosis factor. *Circ. Shock.* 24: 111-21 (1988)

Bagby GJ, Lang CH, Skrepnik N, Spitzer JJ. Attenuation of glucose metabolic changes resulting from TNF-alpha administration by adrenergic blockade. *Am J Physiol.* 262:R628-35 (1992).

Balazs, C., Kiss, E. Immunological aspects of the effect of pentoxifylline (Trental). *Acta Microbiol. Immunol. Hung.* 41: 121-126 (1994)

Balducci L and Hardy C. Cancer and malnutrition -a critical interaction: a review. *Am. J. Hematol.* 18: 91-103 (1985)

Balducci L, Hardy C. Cancer and malnutrition--a critical interaction: a review. *Am J Hematol.* 18:91-103 (1985).

Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. *Annu Rev Immunol.* 14:649-83 (1996)

Balkwill FR, Burke F, Talbot D, Tavernier J, Osborne R, Naylor S, Durbin H and Fiers W. Evidence for tumor necrosis factor/cachectin production in cancer. *Lancet.* 2: 1229-32 (1987)

Barbe P, Millet L, Larrouy D, Galitzky J, Berlan M, Louvet JP and Langin D. Uncoupling protein-2 messenger ribonucleic acid expression during very-low-calorie diet in obese premenopausal women. *J. Clin. Endocrinol. Metab.* 83: 2450-3 (1998)

Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med.* 336:1066-71 (1997)

Bartlett DL, Charland S, Torosian MH. Growth hormone, insulin, and somatostatin therapy of cancer cachexia. *Cancer.* 73:1499-504 (1994)

Bartlett DL, Charland SL and Torosian MH. Reversal of tumor associated hyperglucanogemia as treatment for cancer cachexia. *Surgery.* 118: 87-97 (1995)

Beck SA and Tisdale MJ. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. *Cancer Res.* 47: 5919-23 (1987)

Beck SA, Mulligan HD and Tisdale MJ. Lipolytic factor associated with murine and human cancer cachexia. *J. Natl. Cancer Inst.* 82: 1922-6 (1990)

Beck, S.A., Tisdale, M.J. Effect of insulin on weight loss and tumor growth in a cachexia model. *Br. J. Cancer* 59: 677-681 (1989)

- Beckerle, M.C., Burridge, K., De Martino, G.N., Croall, D.E. Colocalization of calcium-dependent protease II and one of its substrates at sites of cell adhesion. *Cell* 51: 569-577 (1987)
- Beg AA and Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. *Science*. 274: 782-4 (1996)
- Begg RW. Tumor-host relations. *Adv. Cancer Res.* 5: 1-54 (1958)
- Begum N and Ragolia L. Effect to tumor necrosis factor on insulin action in cultured rat skeletal muscle cells. *Endocrinology*. 137: 2441-6 (1996a)
- Behrens A, Sibilio M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. *Nat Genet.* 21:326-9 (1999)
- Belizario JE, Katz M, Chenker E and Raw I. Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. *Br. J. Cancer.* 63: 705-10 (1991)
- Belizario JE, Lorite MJ, and Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. *Br J Cancer* 84: 1135-1140, (2001)
- Benbrook DM, Jones NC. Different binding specificities and transactivation of variant CRE's by CREB complexes. *Nucleic Acids Res.* 22:1463-9 (1994)
- Bengal E, Ransone L, Scharfmann R, Dwarki VJ, Tapscott SJ, Weintraub H, Verma IM. Functional antagonism between c-Jun and MyoD proteins: a direct physical association. *Cell.* 68:507-19 (1992)
- Beraud C, Henzel WJ, Baeuerle PA. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. *Proc Natl Acad Sci U S A.* 96:429-34 (1999)
- Berk M, Desai SY, Heyman HC, Colmenares C. Mice lacking the ski proto-oncogene have defects in neurulation, craniofacial, patterning, and skeletal muscle development. *Genes Dev.* 11:2029-39 (1997)
- Bernstein IL, Taylor EM and Bentson KL. TNF-induced anorexia and learned food aversions are attenuated by area postrema lesions. *Am. J. Physiol.* 260: R906-R910 (1991)
- Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R and Cerami A. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. *Nature.* 316: 552-4 (1985a)
- Beutler B, Milsark IW and Cerami A. Cachectin/tumor necrosis factor: productions, distributions and metabolic fate in vivo. *J. Immunol.* 135: 3972-7 (1985b)
- Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. *J Investig Med.* 43:227-35 (1995).
- Bibby MC, Double JA, Ali SA, Fearon KC, Brennan RA, Tisdale MJ. Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. *J Natl Cancer Inst.* 78:539-46 (1987).
- Bielefeldt-Ohmann, H., Marzo, A.L., Himbeck, R.P., Jarnicki, A.J., Robinson, B.W., Fitzpatrick, D.R. Interleukin-6 involvement in mesothelioma pathobiology: inhibition of interferon- $\gamma$  immunotherapy. *Cancer Immunol. Immunother.* 40: 241-250 (1995)
- Billiau A and Vandekerckhove F. Cytokines and their interaction with other inflammatory mediators in the pathogenesis of sepsis and septic shock. *Eur. J. Clin. Invest.* 21:559-73 (1991)
- Bischoff R, The satellite cell and muscle regeneration. In: *Myology*. Eds: Engel A, Franzini-Armstrong C, McGraw-Hill, NY. 1, 97-118 (1994).
- Black BL and Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. *Annu Rev Cell Dev Biol* 14: 167-196, (1998)

- Black BL, Molkentin JD, Olson EN. Multiple roles for the MyoD basic region in transmission of transcriptional activation signals and interaction with MEF2. *Mol Cell Biol.* 18:69-77 (1998)
- Black BL, Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. *Annu Rev Cell Dev Biol.* 14:167-96 (1998)
- Blackwell JB. *Gut.* 2:367 (1961)
- Blau, H.M., Grace, K.P., Pavlath, E.C., Hardeman, C.C., Silberstein, S.G., Webster, S.G., Miller, S.C., Webster, C. Plasticity of the differentiated state. *Science* 230: 758-766 (1985)
- Blomstrand E, Hassmen P, Ekblom B and Newsholme EA. Administration of branched-chain amino acids during sustained exercise--effects on performance and on plasma concentration of some amino acids. *Eur. J. Appl. Physiol. Occup. Physiol.* 63: 83-8 (1991)
- Blough E, Dineen B, Esser K. Extraction of nuclear proteins from striated muscle tissue. *Biotechniques.* 26:202-4 (1999)
- Bornemann A, Maier F, and Kuschel R. Satellite cells as players and targets in normal and diseased muscle. *Neuropediatrics* 30: 167-175, (1999)
- Bossola M, Muscaritoli M, Costelli P, Bellantone R, Pacelli F, Busquets S, Argilés J, López-Soriano FJ, Civello IM, Baccino FM, Rossi Fanelli F, Doglietto GB. Increased muscle ubiquitin mRNA levels in gastric cancer patients. *Am J Physiol Regul Integr Comp Physiol.* 280:R1518-23 (2001)
- Bossola M, Muscaritoli M, Costelli P, Nanni G, Tazza L, Panocchia N, Busquets S, Argilés J, López-Soriano FJ, Grieco G, Baccino FM, Fanelli FR, Castagneto M, Luciani G. Muscle ubiquitin m-RNA levels in patients with end-stage renal disease on maintenance hemodialysis. *J Nephrol.* 15:552-7 (2002)
- Bour BA, O'Brien MA, Lockwood WL, Goldstein ES, Bodmer R, Taghert PH, Abmayr SM, Nguyen HT. *Drosophila* MEF2, a transcription factor that is essential for myogenesis. *Genes Dev.* 9:730-41 (1995)
- Boyle WJ, Smeal T, Defize LH, Angel P, Woodgett JR, Karin M, Hunter T. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. *Cell.* 64:573-84 (1991)
- Braun T, Arnold HH. Inactivation of Myf-6 and Myf-5 genes in mice leads to alterations in skeletal muscle development. *EMBO J.* 14:1176-86 (1995).
- Braun T, Rudnicki MA, Arnold HH, Jaenisch R. Targeted inactivation of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal death. *Cell.* 71:369-82 (1992).
- Brennan MF. Total parenteral nutrition in the cancer patient. *N. Engl. J. Med.* 305: 375 (1981)
- Brennan MF. Uncomplicated starvation versus cancer cachexia. *Cancer Res.* 37:2359-64 (1977).
- Brenner DA, Buck M, Feitelberg SP, Chojkier M. Tumour necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. *J. Clin. Invest.* 85: 248-55 (1990)
- Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. *Nature.* 337:661-3 (1989)
- Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, Delafontaine P. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. *Endocrinology.* 142:1489-96 (2001).
- Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. *J Clin Invest.* 97:2509-16 (1996).
- Brooks SL, Neville AM, Rothwell NJ, Stock MJ, Wilson S. Sympathetic activation of brown adipose tissue thermogenesis in cachexia. *Biosci. Rep.* 1: 509-517 (1981)

Brown JR, Nigh E, Lee RJ, Ye H, Thompson MA, Saudou F, Pestell RG, Greenberg ME. Fos family members induce cell cycle entry by activating cyclin D1. *Mol Cell Biol.* 18:5609-19 (1998)

Bruera, E., MacMillan, K., Kuehn, N., Hanson, J., MacDonald, N. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer. *Cancer* 66: 1279-1282 (1990)

Buck M and Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. *EMBO J.* 15:1753-65 (1996)

Bullo-Bonet M, García-Lorda P, López-Soriano FJ, Argilés JM and Salas-Salvadó J. Tumour necrosis factor, a key role in obesity? *FEBS Lett.* 451: 215-9 (1999)

Buse MG and Reid SS. Leucine. A possible regulator of protein turnover in muscle. *J. Clin. Invest.* 56: 1250-61 (1975)

Busquets S, Alvarez B, Llovera M, Agell N, López-Soriano FJ, Argilés JM. Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. *J Cell Physiol.* 184:380-4 (2000)

Busquets S, Alvarez B, López-Soriano FJ, Argilés JM. Branched-chain amino acids: a role in skeletal muscle proteolysis in catabolic states? *J Cell Physiol.* 191:283-9 (2002)

Busquets S, Carbo N, Almendro V, Figueras M, López-Soriano FJ, Argilés JM. Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia? *FEBS Lett.* 505:255-8 (2001)

Busquets S, Carbo N, Almendro V, Quiles MT, López-Soriano FJ, Argilés JM. Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. *Cancer Lett.* 167:33-8 (2001)

Buzby GP, Mullen JL, Stein TP, Miller EE, Hobbs CL, Rosato EF. Host-tumor interaction and tumor supply. *Cancer.* 45: 2940-2949 (1980)

Byerley LO, Heber D, Bergman RN, Dubria M, Chi J. Insulin action and metabolism in patients with head and neck-cancer. *Cancer.* 67: 2900-6 (1991)

## C

Caelles C, Gonzalez-Sancho JM, Munoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. *Genes Dev.* 11:3351-64 (1997)

Cahlin C, Gelin J, Delbro D, Lonroth C, Doi C, Lundholm K. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. *Cancer Res.* 60:1742-9 (2000)

Cangiano C, Laviano A, Meguid MM, Mulieri M, Conversano L, Preziosa I and Rossi-Fanelli F. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. *J. Natl. Can. Inst.* 88: 550-2 (1996)

Carbó N, Costelli P, Tessitore L, Bagby GJ, López-Soriano FJ, Baccino FM and Argilés JM. Anti-tumour necrosis factor-alpha treatment interferes with changes in lipid metabolism in a tumour cachexia model. *Clin. Sci.* 87: 349-55 (1994)

Carbo N, López-Soriano J, Costelli P, Busquets S, Alvarez B, Baccino FM, Quinn LS, López-Soriano FJ, Argilés JM. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. *Br J Cancer.* 83:526-31 (2000)

Carbo N, López-Soriano J, Tarrago T, Gonzalez O, Llovera M, López-Soriano FJ, Argilés JM. Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth. *Cancer Lett.* 115:113-8 (1997)

Carlson N and Rechsteiner M. Microinjection of ubiquitin: intracellular distribution and metabolism in HeLa cells maintained under normal physiological function. *J. Cell. Biol.* 104: 537-46 (1987)

- Carswell EA, Old LJ, Kassel RJ, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. *Proc. Natl. Acad. Sci. USA.* 72: 3666-70 (1975)
- Cary PD, King DS, Crane-Robinson C, Bradbury EM, Rabbini L, Goodwin G, Johns E. Structural studies on two high-mobility-group proteins from calf thymus HMG-14 and HMG-20 (ubiquitin) and their interaction with DNA. *Eur. J. Biochem.* 112: 577-80 (1980)
- Castrillo A, Diaz-Guerra MJ, Hortelano S, Martin-Sanz P, Bosca L. Inhibition of I $\kappa$ B kinase and I $\kappa$ B phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages. *Mol Cell Biol.* 20:1692-8 (2000)
- Chaloux E, López-Rovira T, Rosa JL, Bartrons R, Ventura F. JunB is involved in the inhibition of myogenic differentiation by bone morphogenetic protein-2. *J Biol Chem.* 273:537-43 (1998)
- Chance WT, Von Meyenfeldt M and Fischer JE. Serotonin depletion by 5,7-dihydroxytryptamine or para-chloroamphetamine does not affect cancer anorexia. *Pharmac. Biochem. Behav.* 18: 115-21 (1983)
- Chance WT. Assessment of the feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. *Peptides.* 17: 797-801 (1996)
- Chance WT. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor bearer rats. *Life Sci.* 54: 1869-1874 (1994)
- Chen CM, Kraut N, Groudine M, Weintraub H. I-mf, a novel myogenic repressor, interacts with members of the MyoD family. *Cell.* 86:731-41 (1996)
- Chiang HL and Dice JF. Peptide sequences that target proteins for enhanced degradation during serum withdrawal. *J. Biol. Chem.* 263: 6797-805 (1988)
- Chiu R, Angel P, Karin M. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. *Cell.* 59:979-86 (1989)
- Chlebowski, R.T., Bulcavage, L., Grosvenor, M., Oktay, E., Block, J.B., Chlebowski, J.S., Ali, I., Elashoff, R. Hydrazine sulfate influence of nutritional status and survival in non-small cell lung cancer. *J. Clin. Oncol.* 8: 9-15 (1990)
- Chopra IJ, Solomon DH, Chopra U, Wu SY, Fischer DA and Nakamura Y. Pathways of metabolism of thyroid hormones. *Rec. Prog. Horm. Res.* 34: 521-67 (1978)
- Ciaraldi TP, Carter L, Mudaliar S, Kern PA and Henry RR. Effects of tumor necrosis factor-alpha on glucose metabolism in cultured human muscle cells from nondiabetic and type 2 diabetic subjects. *Endocrinology.* 139: 4793-800 (1998)
- Ciechanover A and Schwartz AL. How are substrates recognized by the ubiquitin-mediated proteolytic system? *Trends Biochem. Sci.* 14: 483-8 (1989)
- Clark CM and Goodlad GA. Depletion of proteins of phasic and tonic muscles in tumour-bearing rats. *Eur J Cancer* 7:3-9, (1971)
- Coletti D, Yang E, Marazzi G, and Sassoon D. TNF $\alpha$  inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. *EMBO J* 21: 631-642, (2002)
- Coley WB. The treatment of malignant tumours by repeated inoculations of erysipelas; with a report of ten original cases. *Am. J. Med. Sci.* 105: 487-511 (1893)
- Colmenares C, Stavnezer E. The ski oncogene induces muscle differentiation in quail embryo cells. *Cell.* 59:293-303 (1989)
- Conejo R, Lorenzo M. Insulin signaling leading to proliferation, survival, and membrane ruffling in C2C12 myoblasts. *J Cell Physiol.* 187:96-108 (2001)
- Conejo R, Valverde AM, Benito M, Lorenzo M. Insulin produces myogenesis in C2C12 myoblasts by induction of NF- $\kappa$ B and downregulation of AP-1 activities. *J Cell Physiol.* 186:82-94 (2001)
- Coombes RC, Rothwell NJ, Shah P and Stock MJ. Changes in thermogenesis and brown fat activity in response to tumour necrosis factor in the rat. *Biosci. Rep.* 7: 791-9 (1987)

Coombs RW, Collier AC, Allain JP, Nikora B, Leuther M, Gjerset GF and Corey L. Plasma viremia in human immunodeficiency virus infection. *N. Engl. J. Med.* 321: 1626-31 (1989)

Cooper RN, Tajbakhsh S, Mouly V, Cossu G, Buckingham M, and Butler-Browne GS. In vivo satellite cell activation via Myf5 and MyoD in regenerating mouse skeletal muscle. *J Cell Sci* 112: 2895-2901, (1999)

Cornelius P, Enerback S, Bjursell G, Olivecrona T and Pekala PH. Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumor necrosis factor. *Biochem. J.* 249: 765-9 (1988)

Cornelius P, Marlowe M, Pekala PH. Regulation of glucose transport by tumor necrosis factor-alpha in cultured murine 3T3-L1 fibroblasts. *J Trauma.* 30:S15-20 (1990)

Costelli P, Carbó N, Tessitore L, Bagby GJ, López-Soriano FJ, Argilés JM, Baccino FM. Tumor necrosis- $\alpha$  mediates changes in tissue protein turnover in a rat cancer cachexia model. *J. Clin. Invest.* 92: 2783-89 (1993)

Costelli P, Garcia-Martinez C, Llovera M, Carbo N, López-Soriano FJ, Agell N, Tessitore L, Baccino FM, Argilés JM. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. *J Clin Invest* 95: 2367-72, (1995c)

Costelli P, Llovera M, Carbó N, García-Martínez C, López-Soriano FJ, Argilés JM. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). *Cancer Lett.* 95: 33-8 (1995a)

Costelli P, Llovera M, García-Martínez C, Carbó N, López-Soriano FJ, Argilés JM. Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. *Cancer Lett.* 91: 73-8 (1995b)

Creasey AA, Reynolds MT, Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. *Cancer Res.* 46: 5687-90 (1986)

Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Bombesin-like peptides can function as autocrine growth-factors in human small-cell lung-cancer. *Nature.* 361: 823-25 (1985)

## D

da Silva RJ, da Silva MG, Vilela LC, Fecchio D. Cytokine profile of Ehrlich ascites tumor treated with Bothrops jararaca venom. *Mediators Inflamm.* 11:197-201 (2002)

De Blaaw I, Eggermont AM, Deutz NE, De Vries M, Buurman WA, Von Meyenfeldt MF. TNF- $\alpha$  has no direct in vivo metabolic effect on human skeletal muscle. *Int. J. Cancer* 71: 148-154 (1997)

De Wys WD, Begg C, Lavin PT, Band PR, Bennet JM, Bertino JR, Cohen MH, Douglas HO Jr, Engstrom PF. Prognostic effect of weight loss prior to chemotherapy in cancer patients. *Am. J. Med.* 69: 491-497 (1980)

Dehoux MJ, van Beneden RP, Fernandez-Celemin L, Lause PL, Thissen JP. Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. *FEBS Lett.* 544:214-7 (2003)

Dejong CH, Busquets S, Moses AG, Ross JA, Argilés JM, Fearon KC. Resting energy expenditure, and skeletal muscle uncoupling protein and ubiquitin mRNA expression in early pancreatic cancer. *Resultados no publicados* (2004)

Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. *J Biol Chem.* 274:32048-54 (1999)

Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. *J Endocrinol.* 169:453-9 (2001)

Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. *J Biol Chem.* 275:36703-7 (2000)

Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. *Circ Res.* 85:394-402 (1999)

Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. *Cell.* 76:1025-37 (1994)

Derogatis L, MacDonald R. Psychopharmacologic applications to cancer. *Cancer* 50: 1968-73 (1982)

Dessi S, Batetta B, Anchisi C, Pani P, Costelli P, Tessitore L and Baccino FM. Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). *Br. J. Cancer.* 66: 787-93 (1992a)

Dessi S, Batetta B, Pulisci D, Accogli P, Pani P, Broccia G. Total and HDL cholesterol in human hematologic neoplasms. *Int J Hematol.* 54:483-6 (1991).

Dessi S, Batetta B, Pulisci D, Spano O, Cherchi R, Lanfranco G, Tessitore L, Costelli P, Baccino FM and Panni P. Altered pattern of lipid metabolism in patients with lung cancer. *Oncology.* 49: 436-41 (1992b)

Dessi S, Batetta B, Spano O, Bagby GJ, Tessitore L, Costelli P, Baccino FM, Pani P, Argilés JM. Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130). *Br J Cancer.* 72:1138-43 (1995a)

Dessi S, Batetta B, Spano O, Sanna F, Tonello M, Giacchino M, Tessitore L, Costelli P, Baccino FM, Madon E, et al. Clinical remission is associated with restoration of normal high-density lipoprotein cholesterol levels in children with malignancies. *Clin Sci (Lond).* 89:505-10 (1995b)

Deutsch PJ, Hoeffler JP, Jameson JL, Lin JC, Habener JF. Structural determinants for transcriptional activation by cAMP-responsive DNA elements. *J Biol Chem.* 263:18466-72 (1988)

DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. *Nature.* 388:548-54 (1997)

Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA Jr and O'Connor JV. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. *J. Exp. Med.* 163: 1433-50 (1986)

Ding H, Gao XL, Hirschberg R, Vadgama JV, Kopple JD. Impaired actions of insulin-like growth factor 1 on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. *J Clin Invest.* 97:1064-75 (1996)

Douglas RG, Gluckmann PD, Breier BH, McCall JL, Parry B, Shaw JHF. Effects of recombinant IGF-I on protein and glucose metabolism in rTNF-infused lambs. *Am. J. Physiol.* 261: E606-E612 (1991)

Driscoll J and Goldberg AL. The proteasome (multicatalytic protease) is a component of the 1,500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins. *J. Biol. Chem.* 265: 4789-92 (1990)

Du J, Mitch WE, Wang X, Price SR. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B. *J Biol Chem.* 275:19661-6 (2000)

## E

Ebisui C, Tsujinaka T, Morimoto T, Kan K, Iijima S, Yano M, Kominami E, Tanaka K and Mondem M. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteosome) in C2C12 myotubes. *Clin. Sci.* 89: 431-9 (1995)

Eda, H., Tanaka, Y., Ishitsuka, H. 5'-deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice. *Cancer Chemother. Pharmacol.* 29: 1-6 (1991)

Edwards PD, Moldawer LL. Role of cytokines in the metabolic response to stress. *Curr Opin Clin Nutr Metab Care.* 1:187-90 (1998).

Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, Wagner EF. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. *Cell.* 112:181-92 (2003)

Eggstein M, Kreutz FH. A new determination of the neutral fats in blood serum and tissue. I. Principles, procedure, and discussion of the method. *Klin Wochenschr.* 44:262-7 (1966)

Ehrnst A, Sönnnerborg A, Bergdahl S and Strannegard Ö. Efficient isolation of HIV from plasma during different stages of HIV infection. *J. Med. Virol.* 26: 23-32 (1988)

Eisenberg, S. High density lipoprotein metabolism. *J. Lipid Res.* 25: 1017 (1984)

el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. *Cell.* 75:817-25 (1993)

el-Kamar FG, Grossbard ML, Kozuch PS. Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. *Oncologist.* 8:18-34 (2003)

Emery PW, Edwards RH, Rennie MJ, Souhami RL, Halliday D. Protein synthesis in muscle measured in vivo in cachectic patients with cancer. *Br Med J (Clin Res Ed).* 289:584-6 (1984)

Emery PW, Lovell L, Rennie MJ. Protein synthesis measured in vivo in muscle and liver of cachectic tumor-bearing mice. *Cancer Res.* 44:2779-84 (1984)

Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, Gabarre J, Gaillard JP, Brochier J, Raphael M. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. *Blood.* 84:2472-9 (1994)

Engert JC, Berglund EB, Rosenthal N. Proliferation precedes differentiation in IGF-I-stimulated myogenesis. *J Cell Biol.* 135:431-40 (1996)

Ensoli, B., Barillari, G., Gallo, R.C. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. *Immunol Rev.* 127: 147-55 (1992)

Evans RD and Williamson DH. Tumor necrosis factor- $\alpha$  (cachectin) mimics some of the effects of tumor growth on the disposal of a [ $^{14}$ C] lipid load in virgin, lactating and litter-removed rats. *Biochem. J.* 256: 1055-8 (1988)

Evans RD, Argilés JM and Williamson DH. Metabolic effects of tumor necrosis factor- $\alpha$  (cachectin) and interleukin 1. *Clin. Sci.* 77: 357-64 (1989)

Ewton DZ, Falen SL, Florini JR. The type II insulin-like growth factor (IGF) receptor has low affinity for IGF-I analogs: pleiotypic actions of IGFs on myoblasts are apparently mediated by the type I receptor. *Endocrinology.* 120:115-23 (1987)

## F

Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A. Cannabinoids ablate release of TNF $\alpha$  in rat microglial cells stimulated with lipopolysaccharide. *Glia.* 41:161-8 (2003)

Fan J, Char D, Bagby GJ, Gelato MC, Lang CH. Regulation of insulin-like growth factor-I (IGF) and IGF-binding proteins by tumor necrosis factor. *Am. J. Physiol.* 269: R1204-R1212 (1995)

Fearon KCH, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute phase protein response. *Ann. Surg.* 227: 249-54 (1998)

Fearon KCH, Hansell DT, Preston T, Plumb JA, Davies J, Shapiro D, Shenkin A, Calman KC, Burns HJG. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. *Cancer Res.* 48: 2590-5 (1988)

Feingold KR and Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. *J. Clin. Invest.* 80: 184-90 (1987)

Feingold KR, Doerrler W, Dinarello CA, Fiers W, Grunfeld C. Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. *Endocrinology.* 130:10-6 (1992)

Feingold KR, Serio MJ, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates lipid synthesis and secretion. *Endocrinology* 124: 2336-2342 (1989)

Feingold KR, Staprans I, Memon RA, Moser AH, Shigenaga JK, Doerrler W, Dinarello CA, Grunfeld C. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. *J Lipid Res.* 33:1765-76 (1992)

Fenselau A, Wallis K, Morris HP. Acetoacetate coenzyme A transferase activity in rat hepatomas. *Cancer Res.* 35: 2315-20 (1975)

Fernstrom JD and Wurtman RJ. Brain serotonin content: physiological dependence on plasma tryptophan levels. *Science.* 173: 149 (1971)

Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. *FEBS Lett.* 285: 199-212 (1991a)

Fiers W. Tumor necrosis factors: structure, function, and mechanisms of action. Aggarwal, B.B. and Vilcek, J., eds. Marcel Dekker, New York. (1991b)

Figueras M, Busquets S, Carbo N, Barreiro E, Almendro V, Argilés JM, López-Soriano FJ. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. *FEBS Lett.* 569:201-6 (2004)

Finch JS, St John T, Krieg P, Bonham K, Smith HT, Fried VA, Bowden GT. Overexpression of three ubiquitin genes in mouse epidermal tumors is associated with enhanced cellular proliferation and stress. *Cell Growth Differ.* 3: 269-78 (1992)

Finkel T, Duc J, Fearon ER, Dang CV, Tomaselli GF. Detection and modulation in vivo of helix-loop-helix protein-protein interactions. *J Biol Chem.* 268:5-8 (1993)

Finley D, Bartel B, Varshavsky A. The tails of ubiquitin precursors are ribosomal proteins whose fusion to ubiquitin facilitates ribosome biogenesis. *Nature.* 338: 394-401 (1989)

Finley D, Özkaynak E, Varshavsky A. The yeast polyubiquitin gene is essential for resistance to high temperature, starvation and other stresses. *Cell.* 48: 1035-46 (1987)

Fischer JE and Hasselgren PO. Cytokines and glucocorticoids in the regulation of the "hepato-skeletal muscle axis" in sepsis. *Am. J. Surg.* 161: 266-71 (1991)

Fisher CJ Jr, Agosti JM, Opal CM, Lowry SF, Balk CA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. *N. Engl. J. Med.* 334: 1697-702 (1996)

Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi Meyrueis C, Bouillaud F, Seldin M, Surwit R, Ricquier D, Warden C. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. *Nat. Genet.* 15: 269-72 (1997)

Fliers JS and Maratos-Flier E. Obesity and the hypothalamus: novel peptides for novel pathways. *Cell.* 92: 437-40 (1998)

- Flores EA, Bistran BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin-1. *J. Clin. Invest.* 83: 1614-22 (1989)
- Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. *Endocr Rev.* 17:481-517 (1996)
- Florini JR, Ewton DZ, Magri KA, Mangiacapra FJ. IGFs and muscle differentiation. *Adv Exp Med Biol.* 343:319-26 (1993)
- Florini JR, Ewton DZ, Magri KA. Hormones, growth factors, and myogenic differentiation. *Annu Rev Physiol.* 53:201-16 (1991)
- Floss T, Arnold HH, Braun T. A role for FGF-6 in skeletal muscle regeneration. *Genes Dev.* 11:2040-51 (1997)
- Fong Y, Moldawer LL, Morano M, Wei H, Barber A, Manogue K, Tracey KJ, Kuo G, Fischman DA, Cerami A, Lowry SF. Cachectin/TNF or IL-1 $\alpha$  induces cachexia with redistribution of body proteins. *Am. J. Physiol.* 256: R659-65 (1989)
- Fried SK, Zechner R. Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. *J Lipid Res.* 30:1917-23 (1989)
- Friedman JM. Leptin, leptin receptors, and the control of body weight. *Nutr. Rev.* 56: 38-46 (1998)
- Froesch, E. Schid, C. Schawander, J., Zapf, J. Actions of insulin-like growth factors. *Annu. Rev. Physiol.* 47: 443-67 (1985)
- Frost RA, Lang CH, Gelato MC. Transient exposure of human myoblast to tumor necrosis factor- $\alpha$  inhibits serum and insulin-like growth factor-I stimulated protein synthesis. *Endocrinology* 138: 4153-9 (1997)
- Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. *J Clin Invest.* 96:1722-9 (1995).
- Fujita J, Tsujinaka T, Yano M, Ebisui C, Saito H, Katsume A, Akamatsu K, Ohsugi Y, Shiozaki H, Monden M. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. *Int J Cancer.* 68:637-43 (1996)
- Fulks RM, Li JB, Goldberg AL. Effects of insulin, glucose, and amino acids on protein turnover in rat diaphragm. *J. Biol. Chem.* 250: 290-8 (1975)
- Furuno K and Goldberg AL. The activation of protein degradation in muscle by Ca<sup>2+</sup> or muscle injury does not involve a lysosomal mechanism. *Biochem. J.* 237: 859-64 (1986)
- Furuno K, Goodman MN, Goldberg AL. Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy. *J. Biol. Chem.* 265: 8550-7 (1990)

## G

- García-Martínez C, Agell N, Llovera M, López-Soriano FJ, Argilés JM. Tumour necrosis factor-alpha increases the ubiquitination of rat skeletal muscle proteins. *FEBS Lett.* 323: 211-4 (1993)
- García-Martínez C, Llovera M, Agell N, López-Soriano FJ, Argilés JM. Ubiquitin gene expression in skeletal muscle is increased by tumour necrosis factor-alpha. *Biochem. Biophys. Res. Commun.* 201: 682-6. (1994a)
- García-Martínez C, Llovera M, López-Soriano FJ, Argilés JM. The effects of endotoxin administration on blood amino acid concentrations: similarities with sepsis. *Cell. Mol. Biol.* 39: 537-42 (1993)
- García-Martínez C, López-Soriano FJ, Argilés JM. Interleukin-6 does not activate protein breakdown in rat skeletal muscle. *Cancer Lett.* 76: 1-4 (1994b)

García-Martínez C, López-Soriano FJ, Argilés JM. Amino acid uptake in skeletal muscle of rats bearing the Yoshida AH-130 ascites hepatoma. *Mol Cell Biochem.* 148:17-23 (1995).

García-Martínez C, Mecanismos moleculares implicados en el desgaste muscular durante la caquexia asociada al crecimiento tumoral. Tesis Doctoral. 122-30 (1995)

Garland PB and Randle PJ. A rapid enzymatic assay for glycerol. *Nature.* 196:987-8 (1962)

Garry DJ, Meeson A, Elterman J, Zhao Y, Yang P, Bassel-Duby R, Williams RS. Myogenic stem cell function is impaired in mice lacking the forkhead/winged helix protein MNF. *Proc Natl Acad Sci U S A.* 97:5416-21 (2000)

Garry DJ, Yang Q, Bassel-Duby R, Williams RS. Persistent expression of MNF identifies myogenic stem cells in postnatal muscles. *Dev Biol.* 188:280-94 (1997)

Gehr G, Braun T and Lesslauer W. Cytokines, receptors and inhibitors. *Clin. Invest.* 79: 64-9 (1992)

Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. *Annu Rev Immunol.* 16:225-60 (1998)

Gibbs J and Smith JP. Effect of brain-peptides on satiety. In: Obesity. Eds. Björntorp, P., Brodoff, B.N., J.B. Lippincott Company, Philadelphia. pp. 399-410 (1992)

Glotzer M, Murray AW and Kirschner MW. Cyclin is degraded by the ubiquitin pathway. *Nature.* 349: 132-8 (1991)

Goldberg AL and Rock KL. Proteolysis, proteasomes and antigen presentation. *Nature.* 357: 375-9 (1992)

Goldberg, R.M., Loprinzi, C.L., Mailliard, J.A. et al. Pentoxifiline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. *J. Clin. Oncol.* 13; 2856-9 (1995)

Goldknopf. I.L., Busch, H. Remarkable similarities of peptide fingerprints of histone 2A and nonhistone chromosomal protein A24. *Biochem. Biophys. Res. Commun.* 65: 951-60 (1975)

Goodlad GAJ, Tee MK, Clark CM. Leucine oxidation and protein degradation in the extensor digitorum longus and soleus of the tumor-bearing host. *Biochem. Med.* 23: 143-7 (1981)

Goodman MN. Tumor necrosis factor induces skeletal muscle protein breakdown in rats. *Am. J. Physiol.* 260: E727-30 (1991)

Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. *Cancer.* 63:330-4 (1989).

Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. *Cancer.* 63:330-4 (1989)

Grounds MD. Age-associated changes in the response of skeletal muscle cells to exercise and regeneration. *Ann N Y Acad Sci.* 854:78-91 (1998)

Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J and Feingold KR. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. *J. Clin. Invest.* 97: 2152-7 (1996)

Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. *Mol Cell Biol.* 19:5785-99 (1999)

Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. *Science.* 289:2363-6 (2000)

## H

Haas AL and Bright PM. The immunochemical detection and quantitation of intracellular ubiquitin-protein conjugates. *J Biol Chem.* 260:12464-73 (1985)

Haas AL and Riley DA. The dynamics of ubiquitin pools within skeletal muscle. "The ubiquitin system" (Eds. Schlesinger, M., Hershko, A.), pp. 178-185 Cold Spring Harbor Laboratory, New York (1988)

Hai T and Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. *Proc Natl Acad Sci U S A.* 88:3720-4 (1991)

Han HQ, Furuno QF, Goldberg AL. The activation of the ATP-dependent proteolytic system in skeletal muscle during denervation atrophy and fasting. *Federation Proc.* 2: A564 (Abstract) (1988)

Hanada T, Toshinai K, Kajimura N, Nara-Ashizawa N, Tsukada T, Hayashi Y, Osuye K, Kangawa K, Matsukura S, Nakazato M. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. *Biochem Biophys Res Commun.* 301:275-9 (2003)

Hanada T, Toshinai K, Date Y, Kajimura N, Tsukada T, Hayashi Y, Kangawa K, Nakazato M. Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. *Metabolism.* 53:84-8 (2004)

Haranaka K, Satomi N and Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. *Int. J. Cancer.* 34: 263-7 (1984)

Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN, Klein WH. Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. *Nature.* 364:501-6 (1993)

Hata A, Ohno S, Akita Y, Suzuki K. Tandemly reiterated negative enhancer-like elements regulate transcription of a human gene for the large subunit of calcium-dependent protease. *J Biol Chem.* 264:6404-11 (1989)

Heinrichs SC, Menzaghi F, Koob GF. Neuropeptide-Y induced feeding and its control. *Vitam. Horm.* 54: 51-66 (1998)

Helliwell TR, Wilkinson A, Griffiths RD, McClelland P, Palmer TEA, Bone JM. Muscle fiber atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin. *Neuropathol. Appl. Neurobiol.* 24: 507-17 (1998)

Henderson E and Stein R. c-jun inhibits transcriptional activation by the insulin enhancer, and the insulin control element is the target of control. *Mol Cell Biol.* 14:655-62 (1994)

Hengge UR, Baumann M, Maleba R, Brockmeyer NH, Goos M. Oxymethalone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. *Br. J. Nutr.* 75: 129-38 (1996)

Hershko A. The ubiquitin pathway for protein degradation. *Trends Biochem. Sci.* 16: 265-8 (1991)

Herz J and Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. *Proc Natl Acad Sci U S A.* 90:2812-6 (1993)

Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. *Genes Dev.* 7:2135-48 (1993)

Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. *Proc Natl Acad Sci U S A.* 90:9901-5 (1993)

Hilberg F, Aguzzi A, Howells N, Wagner EF. c-jun is essential for normal mouse development and hepatogenesis. *Nature.* 365:179-81 (1993)

- Hirokawa J, Sakaue S, Tagami S, Kawakami Y, Sakai M, Nishi S, Nishihira J. Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor- $\alpha$ . *Biochem Biophys Res Commun.* 235:94-8 (1997)
- Ho D, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. *N. Engl. J. Med.* 321: 1621-5 (1989)
- Hobler SC, Wang JJ, Williams AB, Melandri F, Sun X, Fischer JE, Hasselgren PO. Sepsis is associated with increased ubiquitin-conjugating enzyme E214k mRNA in skeletal muscle. *Am. J. Physiol.* 276: R468-73 (1999)
- Hohorst HJ, Kreutz FH, Bücher T. On the metabolic content and the metabolic concentration in the liver of the rat. *Biochem. Z.* 332: 18-46 (1959)
- Homem-de-Bittencourt Junior PI, Pontieri V, Curi R, Lopes OU. Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats. *Braz J Med Biol Res.* 22:1039-42 (1989)
- Hopitzan A, Himmelbauer H, Spevak W, Castanon MJ. The mouse Psm1 gene coding for the alpha-type C2 proteasome subunit: structural and functional analysis, mapping, and colocalization with Pde3b on mouse chromosome 7. *Genomics.* 66:313-23 (2000)
- Hori K, Ehrke MJ, Mace K and Mihich E. Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and  $\gamma$ -interferon. *Cancer Res.* 47: 5868-74 (1987)
- Hotamisligil GS, Arner P, Caro JF, Atkinson RL and Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor- $\alpha$  in human obesity and insulin resistance. *J. Clin. Invest.* 95: 2409-15 (1995)
- Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- $\alpha$ - and obesity-induced insulin resistance. *Science.* 271:665-8 (1996)
- Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- $\alpha$ : Direct role in obesity-linked insulin resistance. *Science.* 259: 87-91 (1993)
- Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. *Arthritis Rheum.* 31: 784-788 (1988)
- Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin M. Abnormal morphogenesis but intact IKK activation in mice lacking the IKK $\alpha$  subunit of I $\kappa$ B kinase. *Science.* 284:316-20 (1999)
- Hurwitz A, Furtado D, Low RR. The effects of endotoxemia and bacteremia on gastrointestinal drug absorption in mice and rats. *J Pharmacol Exp Ther.* 192:236-41 (1975)
- Husmann I, Soulet L, Gautron J, Martelly I, Barritault D. Growth factors in skeletal muscle regeneration. *Cytokine Growth Factor Rev.* 7:249-58 (1996)
- Hussey HJ, Tisdale MJ. Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. *Br J Cancer.* 80:1231-5 (1999)
- Hussey HJ, Tisdale MJ. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. *Int J Cancer.* 87:95-100 (2000)
- Hytlander A, Körner U, Lundholm KG. Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours. *Eur. J. Clin. Invest.* 23: 46-52 (1993)

## I

- Imajoh S, Kawasaki H, Suzuki K. Limited autolysis of calcium-activated neutral protease (CANP): reduction of the  $\text{Ca}^{2+}$ -requirement is due to the  $\text{NH}_2$ -terminal processing of the large subunit. *J. Biochem.* 100: 633-42 (1986)

Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, Peyron JF. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. *Cell*. 86:787-98 (1996)

Incelet RI, Peacock JL, Gorschboth CM, Norton JA. Gluconeogenesis in the tumor-influenced rat hepatocyte: importance of tumor burden, lactate, insulin, and glucagon. *J. Natl. Can. Inst.* 39: 1039 (1987)

Inui A. Feeding and body weight regulation by hypothalamic-mediation of the levels of leptin. *Trend. Neurosci.* 22: 62-67 (1999)

Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. *CA Cancer J Clin.* 52:72-91 (2002).

## J

Jaaskelainen T, Pirskanen A, Ryhanen S, Palvimo JJ, Deluca HF, Maenpaa PH. Functional interference between AP-1 and the vitamin D receptor on osteocalcin gene expression in human osteosarcoma cells. *Eur J Biochem.* 224:11-20 (1994)

Jagoe RT and Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? *Curr Opin Clin Nutr Metab Care* 4: 183-190, (2001)

Jasani B, Donaldson LJ, Ratcliff JG and Sokhi GS. Mechanisms of impaired glucose tolerance in patients with neoplasia. *Br. J. Cancer.* 38: 287-92 (1978)

Jensen PB, Blume N, Mikkelsen JD, Larsen PJ, Jensen HI, Holst JJ and Madsen OD. Transplantable rat glaucoma cause acute onset of severe anorexia and adipisia despite highly elevated NPY mRNA levels in the hypothalamic arcuate nucleus. *J. Clin. Invest.* 101: 503-510 (1998)

Jentsch S. The ubiquitin-conjugation system. *Annu. Rev. Genet.* 26: 179-207 (1992)

Jimenez-Chillaron JC, Newgard CB, Gomez-Foix AM. Increased glucose disposal induced by adenovirus-mediated transfer of glucokinase to skeletal muscle in vivo. *FASEB J.* 13:2153-60 (1999)

Jimenez-Chillaron JC, Telemaque-Potts S, Gomez-Valades AG, Anderson P, Newgard CB, Gomez-Foix AM. Glucokinase gene transfer to skeletal muscle of diabetic Zucker fatty rats improves insulin-sensitive glucose uptake. *Metabolism.* 51:121-6 (2002)

Johnson ES, Gonda DK and Varshavsky A. Cis/trans recognition and subunit-specific degradation of short-lived proteins. *Nature.* 265: 287-91 (1990)

Johnson G, Refolo LM, Merrill CR and Wallace W. Altered expression and phosphorylation of amyloid precursor protein in heat shocked neuronal PC12 cells. *Brain Res. Mol. Brain Res.* 19:140-8 (1993)

Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. *Cell.* 62:1189-204 (1990)

## K

Kabadi UM, Reust CS, Kabadi MU. Weight gain, improvement in metabolic profile, and CD4 count with insulin administration in an AIDS patient. *AIDS Patient Care STDS.* 14:575-9 (2000)

Kalden-Nemeth D, Grebmeier J, Antoni C, Manger B, Wolf F, Kaldfen JR. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF- $\alpha$  monoclonal antibody therapy. *Rheumatol. Int.* 16: 249-55 (1997)

Kaliman P, Canicio J, Testar X, Palacín M, Zorzano A. Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-kappaB and inducible nitric-oxide

- synthase define a common myogenic signaling pathway. *J Biol Chem.* 274:17437-44 (1999)
- Kamei Y, Xu L, Heinzl T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. *Cell.* 85:403-14 (1996)
- Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia. *Cancer* 65: 2657-2662 (1990)
- Karin M, Liu Z, Zandi E. AP-1 function and regulation. *Curr Opin Cell Biol.* 9:240-6 (1997)
- Karin M. The beginning of the end: I $\kappa$ B kinase (IKK) and NF- $\kappa$ B activation. *J Biol Chem.* 274:27339-42 (1999)
- Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. *J Biol Chem.* 270:16483-6 (1995)
- Kavetsky RE, Samundgean EM and Butenko ZA. Changes in functional state of adrenal cortex during development of tumours. *Acta Union Int. Contra Cancrum.* 18: 115-7 (1962)
- Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S, Manda T, Tomoi M, Kida I, Higaki J, Kaneda Y, Shimomura K, Ogihara T. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. *Gene Ther.* 6:91-7 (1999)
- Kawamura I, Morishita R, Tsujimoto S, Manda T, Tomoi M, Tomita N, Goto T, Ogihara T, Kaneda Y. Intravenous injection of oligodeoxynucleotides to the NF- $\kappa$ B binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. *Gene Ther.* 8:905-12 (2001)
- Kern PA. Recombinant human tumor necrosis factor does not inhibit lipoprotein lipase in primary cultures of isolated human adipocytes. *J. Lipid Res.* 29: 909-14 (1988a)
- Kern PA and Norton JA. Cancer cachexia. *J. Parent. Enteral. Nutr.* 12: 286-98 (1988b)
- Kettelhut IC, Wing SS and Goldberg AL. Endocrine regulation of protein breakdown in skeletal muscle. *Diabetes Metab. Rev.* 4: 751-72 (1988)
- Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor- $\gamma$ , inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. *Diabetes.* 51:1507-14 (2002)
- Kirschke H and Barrett AJ. Chemistry of lysosomal proteases In: *Lysosomes: Their Role in Protein Breakdown.* Academic Press, London. pp. 193-238 (1987)
- Kirschke H, Langner J, Riemann S, Wiederanders B, Ansorge S and Bohley P. Lysosomal cysteine proteinases. In: *Protein degradation in health and disease.* CIBA Foundation Symposium. 75: 15-35 (1980)
- Kitada S, Hays EF, Mead JF. Lipid mobilizing factor from tumors. *Prog. Lipid Res.* 20: 823-6 (1981)
- Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF- $\alpha$  inhibitor: implications for clinical use. *Clin Immunol Immunopathol.* 81:219-23 (1996)
- Klein, S., Simes, J., Blackburn, G.L. Total parenteral nutrition and cancer clinical trials. *Cancer* 58: 1378-1386 (1986)
- Kliwer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. *Recent Prog Horm Res.* 56:239-63 (2001)
- Kliwer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. *Recent Prog Horm Res.* 56:239-63 (2001)
- Kou K, Rotwein P. Transcriptional activation of the insulin-like growth factor-II gene during myoblast differentiation. *Mol Endocrinol.* 7:291-302 (1993)

Kozack W, Poli V, Soszynski D, Conn CA, Leon LR and Kluger MJ. Sickness behavior in mice deficient in interleukin-6 during turpentin abscess and influenza pneumonitis. *Am. J. Physiol.* 272: R621-R630 (1997)

Kralovic BC, Zepp EA and Cenedella RJ. Studies of mechanism of carcass fat depletion in experimental cancer. *Eur. J. Cancer* 13: 1091-7 (1977)

Krause R, James JH, Ziparo V and Fischer JE. Brain tryptophan and the neoplastic anorexia-cachexia syndrome. *Cancer.* 44: 1003-8 (1979)

Krentz AJ, Koster FT, Crist D, Finn K, Boyle PJ, Schade DS. Beneficial antropometric effects of human growth hormone in the treatment of AIDS. (Abstract) *Clin. Res.* 39: 220A (1991)

Kumara-Siri MH, Lee K, Surks MI. Regulation of thyrotropin secretion in rats bearing the Walker 256 carcinoma. *Endocrinology.* 109: 1760-8 (1981)

Kuroda T, Shida H. Angiotensin II-induced myocardial damage with a special reference to low cardiac output syndrome. *Jpn Heart J.* 24:235-43 (1983)

Kurzrock R. The role of cytokines in cancer-related fatigue. *Cancer* 92: 1684-1688, (2001)

Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP, Brennan RG, Roberts SG, Green MR, Goodman RH. Nuclear protein CBP is a coactivator for the transcription factor CREB. *Nature.* 370:223-6 (1994)

## L

Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. *Am. J. Med.* 85: 289-91 (1988)

Lamph WW, Dwarki VJ, Ofir R, Montminy M, Verma IM. Negative and positive regulation by transcription factor cAMP response element-binding protein is modulated by phosphorylation. *Proc Natl Acad Sci U S A.* 87:4320-4 (1990)

Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM. Induction of proto-oncogene JUN/AP-1 by serum and TPA. *Nature.* 334:629-31 (1988)

Lang CH, Dobrescu C and Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. *Endocrinology.* 130: 43-52 (1992)

Lang CH. Beta-adrenergic blockade attenuates insulin resistance induced by tumor necrosis factor. *Am. J. Physiol.* 264: R984-R991 (1993)

Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. *FASEB J.* 15:1169-80 (2001)

Langen RC, Van Der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. *FASEB J.* 18:227-37 (2004)

Langlands K, Yin X, Anand G, and Prochownik EV. Differential interactions of Id proteins with basic-helix-loop-helix transcription factors. *J Biol Chem* 272: 19785-19793, (1997)

Lardeaux BR and Mortimore GF. Amino acid and hormonal control of macromolecular turnover in perfused rat liver. Evidence for selective autophagy. *J. Biol. Chem.* 262: 14514-9 (1987)

Lassar AB, Skapek SX, Novitch B. Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. *Curr Opin Cell Biol.* 6:788-94 (1994)

Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. *J Clin Invest.* 98:1897-905 (1996)

Lawson DH, Richmon A, Nixon DW and Rudman D. Metabolic approaches to cancer cachexia. *Annu. Rev. Nutr.* 2: 227-301 (1982)

Layne MD and Farmer SR. Tumor necrosis factor-alpha and basic fibroblast growth factor differentially inhibit the insulin-like growth factor-I induced expression of myogenin in C2C12 myoblasts. *Exp Cell Res* 249: 177-87, (1999)

Lazarus DD, Kambayashi T, Lowry S, Strassmann G. The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-2-mediated cancer cachexia. *Cancer Lett.* 103:71-7 (1996)

Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. *Trends Cell Biol.* 8:397-403 (1998)

Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landwatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fischer SM, Livi GP, White JR, Adams JL, Young PR. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. *Nature.* 372: 739-46 (1994)

Lee KH, Baek MY, Moon KY, Song WK, Chung CH, Ha DB, Kang MS. Nitric oxide as a messenger molecule for myoblast fusion. *J Biol Chem.* 269:14371-4 (1994)

Lee KH, Kim DG, Shin NY, Song WK, Kwon H, Chung CH, Kang MS. NF-kappaB-dependent expression of nitric oxide synthase is required for membrane fusion of chick embryonic myoblasts. *Biochem J.* 324:237-42 (1997)

Lee MA, Cai L, Hubner N, Lee YA, Lindpaintner K. Tissue- and development-specific expression of multiple alternatively spliced transcripts of rat neuronal nitric oxide synthase. *J Clin Invest.* 100:1507-12 (1997)

Lee MD, Zentella A, Pekala PH and Cerami A. Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. *Proc. Natl. Acad. Sci. USA.* 84: 2590-4 (1987)

Lehtinen SK, Rahkila P, Helenius M, Korhonen P, Salminen A. Down-regulation of transcription factors AP-1, Sp-1, and NF-kappa B precedes myocyte differentiation. *Biochem Biophys Res Commun.* 229:36-43 (1996).

Leibowitz SF. The role of serotonin in eating disorders. *Drugs.* 399: 33 (1990)

Lemercier C, To RQ, Carrasco RA, Konieczny SF. The basic helix-loop-helix transcription factor Mist1 functions as a transcriptional repressor of myoD. *EMBO J.* 17:1412-22 (1998)

Lenhard JM, Lancaster ME, Paulik MA, Weiel JE, Binz JG, Sundseth SS, Gaskill BA, Lightfoot RM, Brown HR. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. *Diabetologia.* 42:545-54 (1999)

Leong MM and Fox GR. Luminescent detection of immunodot and western blots. *Methods Enzymol.* 184:442-51 (1990)

Levin L and Gevers W. Metabolic alterations in cancer II. *S. Afr. Med. J.* 59: 553-6 (1981)

Li J, O'Malley BW, Wong J. p300 requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin. *Mol Cell Biol.* 20:2031-42 (2000)

Li JB and Goldberg AL. Effects of food deprivation on protein synthesis and degradation in rat skeletal muscles. *Am. J. Physiol.* 231: 441-8 (1976)

Li L, Chambard JC, Karin M, Olson EN. Fos and Jun repress transcriptional activation by myogenin and MyoD: the amino terminus of Jun can mediate repression. *Genes Dev.* 6:676-89 (1992)

Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. *Proc Natl Acad Sci U S A.* 95:13012-7 (1998)

Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. *Science.* 284:321-5 (1999)

Li T, Chen YH, Liu TJ, Jia J, Hampson S, Shan YX, Kibler D, Wang PH. Using DNA microarray to identify Sp1 as a transcriptional regulatory element of insulin-like growth factor 1 in cardiac muscle cells. *Circ Res.* 93:1202-9 (2003)

- Li YP and Reid MB. Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. *Curr Op Reum* 13: 483-7, (2001)
- Li YP, Reid MB. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. *Am J Physiol Regul Integr Comp Physiol*. 279:R1165-70 (2000)
- Li YP, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. *FASEB J*. 12:871-80 (1998)
- Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. *J Exp Med*. 189:1839-45 (1999)
- Lieberman SA, Butterfield GE, Harrison D, Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with acquired immunodeficiency syndrome. *J. Clin. Endocrinol. Metab*. 78: 404-10 (1994)
- Lilly B, Zhao B, Ranganayakulu G, Paterson BM, Schulz RA, Olson EN. Requirement of MADS domain transcription factor D-MEF2 for muscle formation in *Drosophila*. *Science*. 267:688-93 (1995)
- Lin J, Page KA, Della-Fera MA, Baile CA. Evaluation of adipocyte apoptosis by laser scanning cytometry. *Int J Obes Relat Metab Disord*. 31 (2004)
- Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. *Science*. 276:1404-7 (1997)
- Ling L, Cao Z, Goeddel DV. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. *Proc Natl Acad Sci U S A*. 95:3792-7 (1998)
- Lissoni P., Paolorossi, F., Tancini, G., Barni, S., Ardizzoia, F., Brivio, B., Zubelewicz, B., Chatikhine, V. Is there a role for melatonin in the treatment of neoplastic cachexia? *Eur. J. Cancer* 32A: 1340-1343 (1996)
- Lissoni P, Rovelli F, Meregalli S, Fumagalli L, Musco F, Brivio F, Brivio O, Esposti G. Melatonin as a new possible anti-inflammatory agent. *J Biol Regul Homeost Agents*. 11:157-9 (1997)
- Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). *Cell*. 75:59-72 (1993)
- Liviano A, Meguid MM, Yang ZJ, Gleason JR, Cangiano C, Rossi-Fanelli F. Cracking the riddle of cancer anorexia. *Nutrition*. 12: 706-10 (1996)
- Llovera M, Carbó N, García-Martínez C, Costelli P, Tessitore L, Baccino FM, Agell N, Bagby GJ, López-Soriano FJ and Argilés JM. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. *Biochem. Biophys. Res. Commun*. 221: 653-5 (1996b)
- Llovera M, García-Martínez C, Agell N, López-Soriano FJ and Argilés JM. Muscle wasting associated with cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. *Int. J. Cancer*. 61: 138-41 (1995)
- Llovera M, García-Martínez C, Agell N, López-Soriano FJ and Argilés JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. *Biochem. Biophys. Res. Commun*. 230: 238-41 (1997)
- Llovera M, García-Martínez C, Agell N, Marzabal M, López-Soriano FJ and Argilés JM. Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. *FEBS Lett*. 338: 311-8 (1994)
- Llovera M, García-Martínez C, Costelli P, Agell N, Carbó N, López-Soriano FJ and Argilés JM. Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. *Cancer Lett*. 99: 7-14 (1996a)
- Llovera M, García-Martínez C, López-Soriano J, Agell N, López-Soriano FJ, García I and Argilés JM. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. *Cancer Lett*. 130: 19-27 (1998b)

Llovera M, García-Martínez C, López-Soriano J, Carbó N, Agell N, López-Soriano FJ and Argilés JM. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. *Mol. Cell. Endocrinol.* 142: 183-9 (1998a)

Llovera M, López-Soriano FJ and Argilés JM. Chronic tumor necrosis factor- $\alpha$  treatment modifies protein turnover in rats tissues. *Biochem. Mol. Biol. Int.* 30: 29-36 (1993b)

Llovera M, López-Soriano FJ and Argilés JM. Effects of tumor necrosis factor- $\alpha$  on muscle protein turnover in vivo in female rats. *J. Natl. Cancer. Inst.* 85: 1334-9 (1993a)

Lockner D, Ericson U, Pettersson A. The effect of cancer on cell turnover in mice organs. *Z Krebsforsch Klin Onkol Cancer Res Clin Oncol.* 77:1-8 (1972)

Long NC, Kunkel SL, Vander AJ and Kluger MJ. Antiserum against TNF enhances LPS fever in the rat. *Am. J. Physiol.* 258: R332-R337 (1990)

López-Soriano J, Carbo N, Tessitore L, López-Soriano FJ, Argilés JM. Leptin and tumor growth in rats. *Int J Cancer.* 81:726-9 (1999)

Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). *Br J Cancer.* 85:297-302 (2001)

Lorite MJ, Thompson MG, Darke JL, Carling G and Tisdale MJ. Mechanism of muscle protein degradation induced by a cancer cachectic factor. *Br. J. Cancer.* 78: 850-6 (1998)

Lowell BB, Susulic V, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB, Kozak LP and Flier JS. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. *Nature (London).* 366: 740-42 (1993)

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 193: 265-275, (1951)

Lowry SF. Cancer cachexia revisited: old problems and new perspectives. *Eur. J. Cancer.* 27: 1-3 (1991)

Luheshi GN, Stefferl A, Turnbull AV, Dascombe MJ, Brower S, Hopkins SJ, Rothwell NJ. Febrile response to tissue inflammation involves both peripheral and brain IL-1 and TNF- $\alpha$  in the rat. *Am. J. Physiol.* 272: R862-R868 (1997)

Lundholm K, Edstrom S, Ekman L, Karlberg I, Bylund AC and Schersten T. Comparative study of influence of malignant tumor on host metabolism in mice and man. Evolution of an experimental model. *Cancer.* 42: 453-61 (1978)

Luo G, Sun X, Hungness E, Hasselgren PO. Heat shock protects L6 myotubes from catabolic effects of dexamethasone and prevents downregulation of NF-kappaB. *Am J Physiol Regul Integr Comp Physiol.* 281:R1193-200 (2001)

Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, Zhou Q. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. *Genes Dev.* 13:2196-206 (1999)

## M

Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. *Int J Clin Pharmacol Ther.* 36:345-9 (1998)

Malik STA. The activity of TNF in experimental cancer models. In: *Tumor necrosis factor: the molecules and their emerging role in medicine.* Beutler, B., ed. Raven Press Ltd. pp. 407-22 (1992)

Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. *Nature.* 385:540-4 (1997)

Männel DN, Jänicke R, Westenfelder U, Orosz PG, Echtenacher B, Kist A, Falk W. Tumor cell-induced TNF production. In: Tumor necrosis factor: structure-function relationship and clinical application. Osawa, T. and Bonavida, B., eds. Basel, Karger. pp. 166-172 (1992)

Mantovani, G., Maccio, A., Esu, S., Lai, P., Santona, M.C., Massa, E., Dessi, D., Melis, G.B., Del Giacco, G.S. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells and cancer patients. *Eur. J. Cancer* 33: 602-7 (1997)

Marinovic AC, Mitch WE, Price SR. Tools for evaluating ubiquitin (UbC) gene expression: characterization of the rat UbC promoter and use of an unique 3' mRNA sequence. *Biochem Biophys Res Commun.* 274:537-41 (2000)

Marshall P, Chartrand N, Worton RG. The mouse dystrophin enhancer is regulated by MyoD, E-box-binding factors, and by the serum response factor. *J Biol Chem* 276: 20719-26, (2001)

Masuno H, Yamasaki N, Okuda H. Purification and characterization of a lipolytic factor (toxohormone-L) from cell-free fluid of ascites sarcoma 180. *Eur. J. Cancer Clin. Oncol.* 20: 1174-85 (1984)

Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. *J. Clin. Invest.* 81: 1925-37 (1988)

Matsui S, Sandberg AA, Negoro S, Sean BK, Goldstein G. Isopeptidase: a novel eukaryotic enzyme that cleaves isopeptide bonds. *Proc. Natl. Acad. Sci. USA.* 79: 1535-9 (1982)

Matthys, P., Heremans, H., Opdenakker, G., Billiau, A. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. *Eur. J. Cancer.* 27: 182-7 (1991a)

Matthys P, Dijkmans R, Proost P, Van Damme J, Heremans H, Sobis H, Billiau A. Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. *Int. J. Cancer.* 49: 77-82 (1991b)

McCarthy DO, Kluger MJ, Vander AJ. Suppression of food intake during infection: is interleukin 1 involved? *Am. J. Clin. Nutr.* 42: 1179-82 (1985)

McCarthy DO and Daun JM. The effects of cyclooxygenase inhibitors on tumor induced anorexia in rats. *Cancer.* 71: 486-92 (1993)

McCarthy H, Crowder R, Dryden S, Williams G. Megesterol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. *Eur. J. Pharmacol.* 265: 99-102 (1994)

McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. *Nature.* 387:83-90 (1997)

Medina MA, Márquez J and Núñez de Castro I. Interchange of amino acids between tumor and host. *Biochem. Med. Metab. Biol.* 48: 1-7 (1992)

Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA. MyoD is required for myogenic stem cell function in adult skeletal muscle. *Genes Dev.* 10:1173-83 (1996)

Meguid MM, Muscaritoli M, Beberly JL, Yang ZJ, Cangiano C, Rossi-Fanelli F. The early cancer anorexia paradigm: changes in plasma free tryptophan and feeding indexes. *J. Parent. Enteral. Nutr.* 16: 56S-59S (1992)

Meguid MM, Yang ZJ and Gleason JR. The gut-brain and brain-gut axis in anorexia: toward an understanding of food intake regulation. *Nutrition.* 12: S57 (1996)

Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A. IKK-1 and IKK-2: cytokine-activated I $\kappa$ B kinases essential for NF- $\kappa$ B activation. *Science.* 278:860-6 (1997)

Mercurio F, Manning AM. Multiple signals converging on NF- $\kappa$ B. *Curr Opin Cell Biol.* 11:226-32 (1999a)

- Mercurio F, Murray BW, Shevchenko A, Bennett BL, Young DB, Li JW, Pascual G, Motiwala A, Zhu H, Mann M, Manning AM. I $\kappa$ B kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. *Mol Cell Biol.* 19:1526-38 (1999b)
- Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. *Diabetes.* 29: 926-30 (1988)
- Miles JM, Rizza RA, Haymond MW, Gerich JE. Effects of acute insulin deficiency on glucose and ketone body turnover in man. *Diabetes.* 29: 926-30 (1980)
- Miles SA, Rezai AR, Salazar-Gonzalez JF, Vander Meyden M, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T. et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. *Proc. Natl. Acad. Sci. U S A.* 87: 4068-4072 (1990)
- Miller SC, Ito H, Blau HM, Torti FM. Tumor necrosis factor inhibits human myogenesis in vitro. *Mol Cell Biol.* 8:2295-301 (1988)
- Mitch WE, Medina R, Griebler S, May RC, England BK, Price SR, Bailey JL and Goldberg AL. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. *J. Clin. Invest.* 93: 2127-33 (1994)
- Mitch WE, Price SR. Transcription factors and muscle cachexia: is there a therapeutic target? *Lancet.* 357:734-5 (2001)
- Mitchelson F. Pharmacological agents affecting emesis. A review. *Drugs.* 43:295-315 (1992)
- Moldawer LL and Copeland EM. Proinflammatory cytokines, nutritional support and the cachectic syndrome. *Cancer.* 79: 1828-1839 (1988)
- Moldawer LL, Georgieff M, Lundholm K. Interleukin 1, tumor necrosis factor- $\alpha$  (cachectin) and the pathogenesis of cancer cachexia. *Clin. Physiol.* 7: 263-274 (1987a)
- Moldawer LL, Svaninger G, Gelin J, Lundholm K. Interleukin 1 and tumor necrosis factor do not regulate protein balance in skeletal muscle. *Am. J. Physiol.* 253: C766-73 (1987b)
- Moley JF, Aamodt R, Rumble W, Kaye W, Norton JA. Body cell mass in cancer-bearing and anorexic patients. *JPEN J Parenter Enteral Nutr.* 11:219-22 (1987a)
- Moley JF, Morrison SD, Norton JA. Preoperative insulin reverses cachexia and decreases mortality in tumor-bearing rats. *J Surg Res.* 43:21-8 (1987b)
- Moley, J.F., Morrison, S.D., Gorschboth, C.M., Norton, J.A. Body composition changes in rats with experimental cachexia: improvements with exogenous insulin. *Cancer Res.* 48: 2784-2787 (1988)
- Montminy MR, Sevarino KA, Wagner JA, Mandel G, Goodman RH. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. *Proc Natl Acad Sci U S A.* 83:6682-6 (1986)
- Moreira AL, Sampaio EP, Zmuidzinis A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor  $\alpha$  by enhancing mRNA degradation. *J Exp Med.* 177:1675-80 (1993)
- Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Filleis RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. *N. Engl. J. Med.* 337: 141-147 (1997).
- Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O and Abe K. Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. *Cancer Res.* 51: 6656-9 (1991)
- Mori, K., Fujimoto-Ouchi, K., Ishikawa, T., Sekiguchi, F., Ishitsuka, H., Tanaka, Y. Murine interleukin-12 prevents the development of cancer cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). *Cancer Lett.* 95: 33-38 (1996)
- Morrison SD. Tumor development on the host. Ed. Liotta, A.L., Kluwer Academic Publishers, Netherlands. pp. 176-213 (1989)

Müller-Taubenberger A, Hagmann J, Noegel A and Gerisch G. Ubiquitin gene expression in *Dictyostelium* is induced by heat and cold shock, cadmium, and inhibitors of protein synthesis. *J. Cell. Biol.* 90: 51-58 (1988)

Muscaritoli M, Meguid MM, Beverly JL, Yang ZJ, Cangiano C, Rossi-Fanelli F. Mechanisms of early tumor anorexia. *J. Surg. Res.* 60: 389-397 (1996)

## N

Nabeshima Y, Hanaoka K, Hayasaka M, Esumi E, Li S, Nonaka I, Nabeshima Y. Myogenin gene disruption results in perinatal lethality because of severe muscle defect. *Nature.* 364:532-5 (1993)

Nakahara W and Fukuoka F. Toxohormone. *Jpn. Med. J.* 1: 271-7 (1948)

Nawabi MD, Block KP, Chakrabarti MC and Buse MG. Administration of endotoxin, tumor necrosis factor, or interleukin 1 to rats activates skeletal muscle branched-chain alpha-keto acid dehydrogenase. *J. Clin. Invest.* 85: 256-63 (1990)

Naya FS and Olson E. MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. *Curr Opin Cell Biol* 11: 683-688, (1999)

Neri, B., Garosi, V.L., Intini, C. Effects of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. *Anticancer Drug* 8: 459-465 (1997)

Ng EH, Rock CS, Lazarus L, Staino-Coico L, Moldawer LL, Lowry SF. Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia. *Am. J. Physiol.* 262: R426-31 (1992)

Nicholson RC, Mader S, Nagpal S, Leid M, Rochette-Egly C, Chambon P. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. *EMBO J.* 9:4443-54 (1990)

Niesler CU, Urso B, Prins JB, Siddle K. IGF-I inhibits apoptosis induced by serum withdrawal, but potentiates TNF-alpha-induced apoptosis, in 3T3-L1 preadipocytes. *J Endocrinol.* 167:165-74 (2000).

Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. *Nature.* 398:252-6 (1999)

Nishimura T, Ohta S, Sato N, Togashi Y, Goto M and Hashimoto Y. Combination tumor immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice. *Int. J. Cancer.* 40: 255-61 (1987)

Nixon DW, Heymsfield SB, Cohen AE, Kutner MH, Anslay J, Lawson DH and Rudman D. Protein-calorie undernutrition in hospitalized cancer patients. *Am J. Med.* 68: 683-90 (1980)

Nixon DW, Kutner M, Heymsfield S, Foltz AT, Carty C, Seitz S, Casper K, Evans WK, Jeejeebhoy KN, Daly JM, et al. Resting energy expenditure in lung and colon cancer. *Metabolism.* 37:1059-64 (1988)

Noguchi Y, Vydellingum NA and Brennan MF. The reversal of increased gluconeogenesis in tumor bearing rat by tumor removal and food intake. *Surgery.* 106: 423-31 (1989)

Nolte LA, Hansen PA, Chen MM, Schluter JM, Gulve EA, Holloszy JO. Short-term exposure to tumor necrosis factor-alpha does not affect insulin-stimulated glucose uptake in skeletal muscle. *Diabetes* 47: 721-6 (1998)

Norton JA, Peacock JL and Morrison SD. Cancer cachexia. *Crit. Rev. Oncol. Hematol.* 7: 289 (1987)

Norton JA, Shamberger R, Stein TP, Milne GW, Brennan MF. The influence of tumor-bearing on protein metabolism in the rat. *J Surg Res.* 30:456-62 (1981a).

Norton JA, Stein TP, Brennan MF. Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer. *Ann Surg.* 194:123-8 (1981b).

Norton JD, Deed RW, Craggs G, Sablitzky F. Id helix-loop-helix proteins in cell growth and differentiation. *Trends Cell Biol* 8: 58-65, (1998)

Novitch BG, Spicer DB, Kim PS, Cheung WL, Lassar AB. pRb is required for MEF2-dependent gene expression as well as cell-cycle arrest during skeletal muscle differentiation. *Curr Biol*. 9:449-59 (1999)

## O

Old LJ. Tumor necrosis factor (TNF). *Science*. 230: 630-2 (1985)

Olson EN, Perry M, Schulz RA. Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. *Dev Biol*. 172:2-14 (1995)

Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. *Nature*. 401:82-5 (1999)

Özkaynak E, Finley D, Solomon MJ and Varshavsky A. The yeast ubiquitin genes: a family of natural gene fusions. *EMBO J*. 6: 1429-39 (1987)

## P

Pain VM, Randall DP and Garlick PJ. Protein synthesis in liver and skeletal muscle of mice bearing an ascites tumor. *Cancer Res*. 44: 1054-7 (1984)

Palladino MA Jr, Refaat-Shalaby M and Kramer SM. Characterization of the antitumor activities of human tumor necrosis factor  $\alpha$  and the comparison with other cytokines: induction of tumor-specific immunity. *J. Immunol*. 138: 4023-32 (1987)

Pallares-Trujillo J, Agell N, García-Martínez C, López-Soriano FJ, Argilés JM. The ubiquitin system: a role in disease? *Med Res Rev* 17: 139-161, (1997)

Pape ME and Kim KH. Effect of tumor necrosis factor on acetyl-coenzyme A carboxylase gene expression and preadipocyte differentiation. *Mol. Endocrinol*. 2: 395-403 (1988)

Park K, Chung M, Kim SJ. Inhibition of myogenesis by okadaic acid, an inhibitor of protein phosphatases, 1 and 2A, correlates with the induction of AP1. *J Biol Chem*. 267:10810-5 (1992)

Patapoutian A, Yoon JK, Miner JH, Wang S, Stark K, Wold B. Disruption of the mouse MRF4 gene identifies multiple waves of myogenesis in the myotome. *Development*. 121:3347-58 (1995)

Patton JS, Peters PM, McCabe J, Crase D, Hansen S, Chen AB and Liggit D. Development of partial tolerance to gastrointestinal effects of high doses of recombinant tumor necrosis factor- $\alpha$  in rodents. *J. Clin. Invest*. 80: 1587-96 (1987)

Patton JS, Shephard HM, Wilkings H, Lewis G, Aggarwal BB, Eessalu TE, Gavin LA, Grunfeld C. Interferons and tumor necrosis factors have similar catabolic effects on 3T3L1 cells. *Proc. Natl. Acad. Sci. USA* 83: 8313-7 (1986)

Pedraza-Alva G, Zingg JM, Jost JP. AP-1 binds to a putative cAMP response element of the MyoD1 promoter and negatively modulates MyoD1 expression in dividing myoblasts. *J Biol Chem*. 269:6978-85 (1994)

Penner CG, Gang G, Wray C, Fischer JE, Hasselgren PO. The transcription factors NF-kappaB and AP-1 are differentially regulated in skeletal muscle during sepsis. *Biochem Biophys Res Commun*. 281:1331-6 (2001)

Penner CG, Gang G, Sun X, Wray C, Hasselgren PO. C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle. *Am J Physiol Regul Integr Comp Physiol*. 282:R439-44 (2002)

Pennica D, Nedwin GE, Hayflick JF, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV. Human tumor necrosis factor: precursor, structure, expression and homology to lymphotoxin. *Nature*. 312: 724-9 (1984)

Peters JM. Proteasomes: protein degradation machines of the cell. *Trends Biochem. Sci*. 19: 377-82 (1994)

Piechaczyk M, Blanchard JM. c-fos proto-oncogene regulation and function. *Crit Rev Oncol Hematol.* 17:93-131 (1994)

Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. *Pharmacol Biochem Behav.* 40:695-700 (1991)

Plata-Salaman CR. Hypothalamus and the control of feeding: fifteen decades of direct association. *Nutrition.* 14:67-70 (1998).

Plata-Salamán CR. Immunoregulators in the nervous system. *Neurosci. Biobehav. Rev.* 15: 185-215 (1991b)

Plata-Salamán CR. Regulation of hunger and satiety in man. *Dig. Dis.* 9: 253-268 (1991a)

Postigo AA, Dean DC. ZEB, a vertebrate homolog of *Drosophila* Zfh-1, is a negative regulator of muscle differentiation. *EMBO J.* 16:3935-43 (1997)

Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA. IGF-I is required for normal embryonic growth in mice. *Genes Dev.* 7:2609-17 (1993)

Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. *J Biol Chem.* 273:32833-41 (1998)

Price SR, Olivecrona T, Pekala PH. Regulation of lipoprotein lipase synthesis by recombinant tumor necrosis factor. The primary role of the hormone in 3T3-L1 adipocytes. *Arch. Biochem. Biophys.* 251: 738-46 (1986)

Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB, Spiegelman BM. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. *Mol Cell.* 8:971-82 (2001)

## Q

Quinn LS, Haugk KL and Grabstein KH. Interleukin 15: a novel anabolic cytokine for skeletal muscle. *Endocrinology.* 136: 3669-72 (1995)

## R

Racker E. Why do tumor cells have a high aerobic glycolysis? *J Cell Physiol.* 89:697-700 (1976)

Ragot T, Vincent N, Chafey P, Vigne E, Gilgenkrantz H, Couton D, Cartaud J, Briand P, Kaplan JC, Perricaudet M, et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. *Nature.* 361:647-50 (1993)

Ranganathan S and Davidson MB. Effects of tumor necrosis factor- $\alpha$  on basal and insulin-stimulated glucose transport in cultured muscle and fat cells. *Metabolism.* 45: 1089-94 (1996)

Ranganayakulu G, Zhao B, Dokidis A, Molkentin JD, Olson EN, Schulz RA. A series of mutations in the D-MEF2 transcription factor reveal multiple functions in larval and adult myogenesis in *Drosophila*. *Dev Biol.* 171:169-81 (1995)

Rawls A, Olson EN. MyoD meets its maker. *Cell.* 89:5-8 (1997)

Rawls A, Valdez MR, Zhang W, Richardson J, Klein WH, Olson EN. Overlapping functions of the myogenic bHLH genes MRF4 and MyoD revealed in double mutant mice. *Development.* 125:2349-58 (1998)

Rechsteiner M. PEST sequences are signals for rapid intracellular proteolysis. *Semin. Cell Biol.* 1: 433-40 (1990)

Rechsteiner M. Ubiquitin-mediated pathways for intracellular proteolysis. *Annu. Rev. Cell. Biol.* 3: 1-30 (1987)

Redman KL and Rechsteiner M. Identification of the long ubiquitin extension as ribosomal protein S27a. *Nature.* 338: 438-40 (1989)

Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an I $\kappa$ B kinase. *Cell*. 90:373-83 (1997)

Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. *Crit. Care Med*. 24: 733-42 (1996)

Riley DA, Bain JLW, Ellis S, Haas AL. Quantitation and immunocytochemical localization of ubiquitin conjugates within rat red and white skeletal muscles. *J. Histochem. Cytochem*. 36: 621-32 (1988)

Rivett AJ. Proteasomes: multicatalytic proteinase complexes. *Biochem. J*. 291: 1-10 (1993)

Rodemann HP, Waxman L and Goldberg AL. The stimulation of protein degradation in muscle by Ca<sup>2+</sup> is mediated by PGE<sub>2</sub> and does not require the calcium activated protease. *J. Biol. Chem*. 257: 8716-23 (1982)

Rofe AM, Conyers RAJ, Bais R, Gamble JR and Vadas MA. The effects of recombinant tumor necrosis factor (cachectin) on metabolism in isolated rat adipocyte, hepatocyte and muscle preparations. *Biochem. J*. 247: 789-92 (1987)

Rogers S, Wells R and Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. *Science*. 234: 364-68 (1986)

Romashkova JA, Makarov SS. NF- $\kappa$ B is a target of AKT in anti-apoptotic PDGF signalling. *Nature*. 401:86-90 (1999)

Rosen KM, Wentworth BM, Rosenthal N, Villa-Komaroff L. Specific, temporally regulated expression of the insulin-like growth factor II gene during muscle cell differentiation. *Endocrinology*. 133:474-81 (1993)

Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I $\kappa$ B kinase. *Nature*. 403:103-8 (2000)

Rossol S, Voth R, Laubenstein HP, Muller WEG, Schröder HC, Meyer zum Buschenfelde KH, Hess G. Interferon production in patients infected with HIV-1. *J. Inn. Dis*. 159: 815-21 (1989)

Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the I $\kappa$ B kinase complex. *Nature*. 395:297-300 (1998)

Rothwell NJ. Central effects of TNF- $\alpha$  on thermogenesis and fever in the rat. *Biosci. Rep*. 8: 345-52 (1988)

Rothwell NJ. Hormones and nutrition in obesity and cachexia. Eds. Müller, M.J., Danforth E, Burger AG, Siedentopp U. Springer-Verlag, Berlin. pp: 77-85 (1990)

Rudnicki MA, Braun T, Hinuma S, Jaenisch R. Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. *Cell*. 71:383-90 (1992)

Ruggiero V and Baglioni C. Synergistic antiproliferative activity of interleukin 1 and tumor necrosis factor. *J. Immunol*. 138: 661-3 (1987)

## S

Sabourin LA, Girgis-Gabardo A, Seale P, Asakura A, Rudnicki MA. Reduced differentiation potential of primary MyoD<sup>-/-</sup> myogenic cells derived from adult skeletal muscle. *J Cell Biol*. 144:631-43 (1999)

Sabourin LA, Rudnicki MA. The molecular regulation of myogenesis. *Clin Genet*. 57:16-25 (2000)

Sachidanandan C, Sambasivan R, Dhawan J. Tristetraprolin and LPS-inducible CXC chemokine are rapidly induced in presumptive satellite cells in response to skeletal muscle injury. *J Cell Sci*. 115:2701-12 (2002)

Sáez S. Adrenal function in cancer: relation to the evolution. *Eur. J. Cancer*. 7: 381-7 (1971)

- Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF- $\alpha$  by human muscle. Relationship to insulin resistance. *J. Clin. Invest.* 97: 1111-6 (1996)
- Sakihama T, Kakidani H, Zenita K, Yumoto N, Kikuchi T, Sasaki T, Kannagi R, Nakanishi S, Ohmori M, Takio K, Titani K, Murachi T. A putative Ca<sup>2+</sup>-binding protein: structure of the light subunit of porcine calpain elucidated by molecular cloning and protein sequence analysis. *Proc. Natl. Acad. Sci. USA.* 82: 6075-9 (1985)
- Samis JA and Elce JS. Immunogold electron-microscopic localization of calpain I in human erythrocytes. *Tromb. Haemost.* 61: 250-3 (1989)
- Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. *J Infect Dis.* 168:408-14 (1993)
- Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor- $\alpha$  production in stimulated human monocytes. *J. Exp. Med.* 173: 699-703 (1991)
- Sánchez-Feutrie M, Santalucia T, Fandos C, Noe V, Viñals F, Brand NJ, Ciudad CJ, Palacín M, Zorzano A. A novel muscle DNA-binding activity in the GLUT1 promoter. *Cell Mol Life Sci.* 61:709-20 (2004)
- Sánchez-Feutrie M, Viñals F, Palacín M, Zorzano A. Identification of a novel proliferation-dependent C-rich element that mediates inhibition of the rat GLUT1 promoter. *Gene.* 322:47-55 (2003)
- Sanchís D, Busquets S, Alvarez B, Ricquier D, Lopez-Soriano FJ, Argiles JM. Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. *FEBS Lett.* 436:415-8 (1998).
- Sanchís D, Fleury C, Chomiki N, Gubern M, Huang Q, Neverova M, Gregoire F, Easlick J, Raimbault S, Levi-Meyrueis C, Miroux B, Collins S, Seldin M, Richard D, Warden C, Bouillaud F, Ricquier D. BMCP1, a novel mitochondrial carrier with high expression in the central nervous system of humans and rodents, and respiration uncoupling activity in recombinant yeast. *J. Biol. Chem.* 273: 34611-5 (1998)
- Sandri M and Carraro U. Apoptosis of skeletal muscles during development and disease. *Int. J. Biochem. Cell Biol.* 31: 1373-90 (1999)
- Schlesinger MJ. The ubiquitin system and the heat shock response. In: *Stress Proteins.* Schlesinger, Santoro, Garaci, eds. Springer-Verlag, Berlín Heidelberg. pp. 81-88 (1990)
- Schrauwen P, Troost FJ, Xia J, Ravussin E, Saris WH. Skeletal muscle UCP2 and UCP3 expression in trained and untrained male subjects. *Int. J. Obes. Relat. Metab. Disord.* 23: 966-72 (1999)
- Seale P and Rudnicki MA. A new look at the origin, function, and "stem-cell" status of muscle satellite cells. *Dev Biol.* 218:115-24 (2000)
- Selby PJ, Hobbs S, Viner C, Jackson E, Smith IE, McElwain TJ. Endogenous tumor necrosis factor in cancer patients. *Lancet.* 8583: 483 (1988)
- Semb H, Peterson J, Tavernier J and Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. *J. Biol. Chem.* 262: 8390-4 (1987)
- Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor- $\alpha$  production by human mononuclear cells. *Int J Immunopharmacol.* 15:409-13 (1993)
- Shapot VS. Some biochemical aspects of the relationship between the tumor and the host. *Adv Cancer Res.* 15:253-86 (1972)
- Shaulian E and Karin M. AP-1 as a regulator of cell life and death. *Nat Cell Biol.* 4:E131-6 (2002)
- Shaulian E and Karin M. AP-1 in cell proliferation and survival. *Oncogene.* 20:2390-400 (2001)

Shaw JH and Wolfe RR. Glucose, fatty-acid, and urea kinetics in patients with severe pancreatitis: the response to substrate infusion and total parenteral nutrition. *Surgery*. 101: 181-91 (1986)

Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H, Kojima M, Kangawa K, Kohno N. Increased plasma ghrelin level in lung cancer cachexia. *Clin Cancer Res*. 9:774-8 (2003).

Sipe JD, Vogel SN, Ryan JL, McAdam KP, Rosenstreich DL. Detection of a mediator derived from endotoxin-stimulated macrophages that induces the acute phase serum amyloid A response in mice. *J Exp Med*. 150:597-606 (1979)

Slein MW. D-glucose determination with hexokinase and glucose-6-phosphate dehydrogenase. "Methods of Enzymatic Analysis" (Ed. Bergmeyer, H.U.), pp. 117-123 Academic Press, Nueva York-Londres (1963)

Smith HJ, Lorite MJ, Tisdale MJ. Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. *Cancer Res*. 59:5507-13 (1999).

Smith HJ, Tisdale MJ. Induction of apoptosis by a cachectic-factor in murine myotubes and inhibition by eicosapentaenoic acid. *Apoptosis*. 8:161-9 (2003).

Smith HJ, Tisdale MJ. Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes. *Br J Cancer*. 89:1783-8 (2003).

Smith HJ, Wyke SM, Tisdale MJ. Role of protein kinase C and NF-kappaB in proteolysis-inducing factor-induced proteasome expression in C(2)C(12) myotubes. *Br J Cancer*. 90:1850-7 (2004).

Soda K, Kawakami M, Kashii A and Miyata M. Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia. *Jpn. J. Cancer Res*. 85: 1124-30 (1994)

Sohmura Y, Nakata K, Yoshida H, Kashimoto S, Matsui Y and Fwuichi H. Recombinant human tumor necrosis factor. Antitumor effect on murine and human tumors transplanted in mice. *Int. J. Immunopharmacol*. 8: 357-68 (1986)

Spalla M, Tsang W, Kuo TH, Giacomelli F and Wienwe J. Purification and characterization of two distinct Ca<sup>2+</sup>-activated proteinases from hearts of hypertensive rats. *Biochim. Biophys. Acta*. 830: 258-66 (1985)

Spiegelman BM and Hotamisligil GS. Through thick and thin: wasting, obesity and TNF- $\alpha$ . *Cell*. 73: 625-7 (1993)

Srivastava MD, Srivastava BI, Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. *Immunopharmacology*. 40:179-85 (1998)

Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation*. 98:2088-93 (1998a)

Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. *Nature*. 393:790-3 (1998b)

Starnes HF, Warren RS, Jeevanandam M, Gabilove JL, Larchian W, Oettgen HF and Brennan MF. Tumor necrosis factor and the acute metabolic response to tissue injury in man. *J. Clin. Invest*. 82: 1321-5 (1988)

Staroukine M, Devriendt J, Decoodt P, Verniory A. Relationships between plasma epinephrine, norepinephrine, dopamine and angiotensin II concentrations, renin activity, hemodynamic state and prognosis in acute heart failure. *Acta Cardiol*. 39:131-8 (1984)

Stephens JM and Pekala PH. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. *J. Biol. Chem*. 266: 21835-45 (1991)

Stewart CE, Newcomb PV, Holly JM. Multifaceted roles of TNF-alpha in myoblast destruction: a multitude of signal transduction pathways. *J Cell Physiol.* 198:237-47 (2004)

Strain AJ. Cancer cachexia in man: a review. *Invest. Cell. Pathol.* 2:181-193 (1979)

Strang, P. The effects of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients. *Anticancer Res.* 17: 657-622 (1997)

Strassmann G, Fong M, Freter CE, Windsor S, D'Alessandro F and Nordan RP. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. *J. Clin. Invest.* 92: 2152-9 (1993)

Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. *Science.* 286:771-4 (1999)

Studley HO. *J. Am. Med. Assoc.* 106: 458 (1936)

Su HY, Bos TJ, Monteclaro FS, Vogt PK. Jun inhibits myogenic differentiation. *Oncogene.* 6:1759-66 (1991)

Sugarman BJ, Aggarwal BB, Hass PE. Recombinant human tumor necrosis factor- $\alpha$ : effects of proliferation on normal and transformed cells in vitro. *Science.* 230: 943-5 (1985)

Sultan KR, Dittrich BT, Leisner E, Paul N, Pette D. Fiber type-specific expression of major proteolytic systems in fast- to slow-transforming rabbit muscle. *Am J Physiol Cell Physiol* 280: C239-C247, (2001)

Szalay K, Razga Z, Duda E. TNF inhibits myogenesis and downregulates the expression of myogenic regulatory factors myoD and myogenin. *Eur J Cell Biol.* 74:391-8 (1997)

## T

Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, Sanjo H, Yoshikawa K, Terada N, Akira S. Limb and skin abnormalities in mice lacking IKKalpha. *Science.* 284:313-6 (1999)

Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, Goeddel DV. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. *Immunity.* 10:421-9 (1999)

Tanaka Y, Eda H, Fugimoto K, Tanaka T, Ishikawa T, Ishitsuka H. Anticachectic activity of 5'-deoxy-5-fluoridine in a murine tumor cachexia model, colon 26 adenocarcinoma. *Cancer Res.* 50: 4528-32 (1990)

Tartaglia LA and Goeddel DV. Two TNF receptors. *Immunol. Today.* 13: 151-3 (1992)

Tawa NE Jr, Goldberg AL. Suppression of muscle protein turnover and amino acid degradation by dietary protein deficiency. *Am J Physiol.* 263:E317-25 (1992a)

Tawa NE Jr, Kettelhut IC, Goldberg AL. Dietary protein deficiency reduces lysosomal and nonlysosomal ATP-dependent proteolysis in muscle. *Am J Physiol.* 263:E326-34 (1992b)

Tayek JA, Heber D, Chlebowski RT. Effective hydrazine sulfate on whole body protein breakdown measured by <sup>14</sup>C-lysine metabolism in lung cancer patients. *Lancet* 11: 241-4 (1987)

Tayek JA, Bistran B, Sheard NF, Zeisel SH, Blackburn GL. Abnormal liver function in malnourished patients receiving total parenteral nutrition: a prospective randomized study. *J Am Coll Nutr.* 9:76-83 (1990)

Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. *J. Am. Coll. Nutr.* 11: 455-6 (1992)

Tayek JA. Effects of tumor necrosis factor alpha on skeletal muscle amino acid metabolism studied in vivo. *J. Am. Coll. Nutr.* 15: 164-8 (1996)

- Temparis S, Asensi M, Taillander D, Aurousseau E, Larbaud D, Obled A, Bechet D, Ferrara M, Estrela JM, Attaix D. Increased ATP-ubiquitin dependent proteolysis in skeletal muscle of tumor bearing rats. *Cancer Res.* 54: 5568-73 (1994)
- Tessitore L, Bonelli G, Baccino FM. Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia. *Biochem J.* 241:153-9 (1987)
- Tessitore L, Costelli P, Baccino FM. Humoral mediation for cachexia in tumour-bearing rats. *Br J Cancer* 67: 15-23, (1993a)
- Tessitore L, Costelli P, Bonetti G, Baccino FM. Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. *Arch Biochem Biophys* 306: 52-8, (1993b)
- Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, Benedetto C, Mussa A. Leptin expression in colorectal and breast cancer patients. *Int J Mol Med.* 5:421-6 (2000)
- Thaloor D, Miller KJ, Gephart J, Mitchell PO, and Pavlath GK. Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. *Am J Physiol* 277: C320-9 (1999)
- Thinakaran G and Bag J. Expression of the protooncogene c-jun is maintained during myogenic differentiation in rat L6 myoblasts. *Biochem Cell Biol.* 71:260-9 (1993a)
- Thinakaran G and Bag J. Regulation of c-jun/AP-1 expression in rat L6 myoblasts. *Biochem Cell Biol.* 71:197-204 (1993b)
- Thinakaran G, Ojala J, Bag J. Expression of c-jun/AP-1 during myogenic differentiation in mouse C2C12 myoblasts. *FEBS Lett.* 319:271-6 (1993c)
- Thompson JR and Wu G. The effect of ketone bodies on nitrogen metabolism in skeletal muscle. *Comp. Biochem. Physiol.* 100: 209-16 (1991)
- Tiao G, Fagan JM, Samuels N, James JH, Hudson K, Lieberman M, Fischer JE and Hasselgren PO. Sepsis stimulates nonlysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle. *J. Clin. Invest.* 94: 2255-64 (1994)
- Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, Fischer JE and Hasselgren PO. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. *J. Clin. Invest.* 99: 163-8 (1997)
- Tisdale MJ. Cancer cachexia. *Anticancer drugs.* 4: 115-25 (1993)
- Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. *Front Biosci* 6: D164-74 (2001)
- Tisdale MJ. Newly identified factors that alter host metabolism in cancer cachexia. *Trends Pharmacol. Sci.* 11: 153-9 (1990)
- Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K and Tisdale MJ. Characterization of a cancer cachectic factor. *Nature.* 379: 739-42 (1996)
- Todorov PT, Field WN and Tisdale MJ. Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). *Br. J. Cancer.* 80: 1734-7 (1999)
- Tollefsen SE, Lajara R, McCusker RH, Clemmons DR, Rotwein P. Insulin-like growth factors (IGF) in muscle development. Expression of IGF-I, the IGF-I receptor, and an IGF binding protein during myoblast differentiation. *J Biol Chem.* 264:13810-7 (1989a)
- Tollefsen SE, Sadow JL, Rotwein P. Coordinate expression of insulin-like growth factor II and its receptor during muscle differentiation. *Proc Natl Acad Sci U S A.* 86:1543-7 (1989b)
- Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Harirri RJ, Fahey TJ, Zentella A, Albert JD, Shires GT and Cerami A. Shock and tissue injury induced by recombinant human cachectin. *Science.* 234: 470-4 (1986a)

Tracey KJ, Lowry SF, Beutler B, Cerami A, Albert JD and Shires GT. Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. *J. Exp. Med.* 164: 1368-73 (1986b)

Tracey KJ, Lowry SF, Fahey TJ, Fong Y, Hesse DG, Beutler B, Manogue K, Calvano SE, Wei H, Albert JD, Cerami A, Shires GT. Cachectin/tumor necrosis factor induces lethal septic shock and stress hormone response in the dog. *Surg. Gynecol. Obstet.* 164: 415-422 (1987).

Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran RS, Cerami A and Lowry SF. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. *J. Exp. Med.* 167: 1211-27 (1988)

Tracey KJ, Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. *Circ Shock.* 35:123-128 (1991)

Tracey KJ and Cerami A. Tumor necrosis factor, other cytokines and disease. *Annu. Rev. Cell. Biol.* 9: 317-43 (1993)

Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner JD, Rom W, Kaplan G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. *Mol Med.* 1:384-97 (1995)

Trausch JS, Grenfell SJ, Handley-Gearhart PM, Ciechanover A, Schwart AL. Immunofluorescent localization of the ubiquitin-activating enzyme, E1, to the nucleus and cytoskeleton. *Am. J. Physiol.* 264: C93-C102 (1993)

Trotta PP. Cytokines: an overview. *Am. J. Reprod. Immunol.* 25: 137-41 (1991)

Tsigos C, Papanicolau DA, Kyrou I, Defensor R, Mitsiadis CS and Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. *J. Clin. Endocrinol. Metab.* 82: 4167-4170 (1997)

Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. *EMBO J.* 11:433-9 (1992)

Turner R, Tjian R. Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers. *Science.* 243:1689-94 (1989)

## U

Uehara A, Sekiya C, Takasugi Y and Namiki M. Neuropeptide Y and the development of cancer anorexia. *Am. J. Physiol.* 257: 613-7 (1989)

## V

Van Buren CT, Rudolph FB, Kulkarni AD, Fanslow WC, Pizzini RP, Kumar S. Effect of diet on transfusion induced immune suppression. *Nutrition.* 6:63-5 (1990)

Van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR, Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. *Am J Physiol.* 261:E457-65 (1991)

Van der Poll T, Sauerwein HP. Tumor necrosis factor- $\alpha$ : its role in the metabolic response to sepsis. *Clin. Sci.* 84: 247-56 (1993)

Van Eys J. Effects of nutritional status in response to therapy. *Cancer Res.* 42: S747-53 (1982)

Van Eys J. Nutrition and cancer: physiological interrelationships. *Annu. Rev. Nutr.* 5: 435-42 (1985)

van Royen M, Carbo N, Busquets S, Alvarez B, Quinn LS, López-Soriano FJ, Argilés JM. DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? *Biochem Biophys Res Commun.* 270:533-7 (2000)

Varshavsky A. The N-end rule. *Cell.* 69: 725-35 (1992)

Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. *Genes Dev.* 9:2723-35 (1995)

Vidal-Puig A, Solanes G, Grujic D, Flier JS, Lowell BB. UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. *Biochem. Biophys. Res. Commun.* 235: 79-82 (1997)

Vigano A, Watanawe S, Bruera E. Anorexia and cachexia in advanced cancer patients. *Cancer Surv.* 21: 99-115 (1994)

Vijay-Kumar S, Bugg CE, Cook WJ. Structure of ubiquitin refined at 1.8 Å resolution. *J. Mol. Biol.* 194: 531-44 (1987)

Viñals F, Fandos C, Santalucia T, Ferre J, Testar X, Palacin M, Zorzano A. Myogenesis and MyoD down-regulate Sp1. A mechanism for the repression of GLUT1 during muscle cell differentiation. *J Biol Chem.* 272:12913-21 (1997)

von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. *Int J Cardiol.* 85:173-83 (2002)

Von Roenn J, Armstrong D, Kotler DP, Cohn DL, Klimas NG. et al. Megesterol acetate in patients with AIDS-related cachexia. *Ann. Intern. Med.* 121: 393-399 (1994)

Von Sydow M, Sönnernborg A, Gaines H, Strannegård Ö. Interferon-alpha and tumor necrosis factor-alpha in serum of patients with various stages of HIV-1 infection. *AIDS Research and Human Retroviruses* 7: 375-80 (1991)

## W

Waalkes TP and Udenfriend MDA. Fluorimetric method for the estimation of tyrosine in plasma and tissues. *J. Lab. Clin. Med.* 50: 733-736 (1957)

Walsh K and Perlman H. Cell cycle exit upon myogenic differentiation. *Curr Opin Genet Dev.* 7:597-602 (1997)

Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. *Science.* 274: 784-7 (1996a)

Wang J and Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. *Science.* 273: 359-61 (1996b)

Wang W, Iresjo BM, Karlsson L, Svanberg E. Provision of rhIGF-I/IGFBP-3 complex attenuated development of cancer cachexia in an experimental tumor model. *Clin Nutr.* 19:127-32 (2000)

Warren RS, Donner DB, Starnes HF Jr and Brennan MF. Modulation of endogenous hormone action by recombinant human tumor necrosis factor. *Proc. Natl. Acad. Sci. USA.* 84: 8619-22 (1987a)

Warren RS, Starnes HF, Gabilove JL, Oettgen HF and Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. *Arch. Surg.* 122: 1396-400 (1987b)

Warren RS, Starnes HF, Alcock N, Calvano S and Brennan MF. Hormonal and metabolic response to recombinant human tumor necrosis factor in rat: in vitro and in vivo. *Am. J. Physiol.* 255: E206-12 (1988)

Warren S. The immediate causes of death in cancer. *Am. J. Med. Sci.* 184: 610-5 (1932)

Watchorn TM, Waddell I, Dowidar N, Ross JA. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. *FASEB J.* 15:562-4 (2001)

Waterhouse C, Jeanpetre N and Keitlson J. Gluconeogenesis from alanine in patients with progressive malignant disease. *Cancer Res.* 39: 1968-72 (1979)

Watzl B, Scuderi P, Watson RR. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. *Int J Immunopharmacol.* 13:1091-7 (1991)

- Weber P, Brown S, Mueller L. <sup>1</sup>H-NMR resonance assignments and secondary structure identification of human ubiquitin. *Biochemistry*. 26: 7282-90 (1987)
- Weintraub H. The MyoD family and myogenesis: redundancy, networks, and thresholds. *Cell*. 75:1241-4 (1993)
- Wenger FA, Peter F, Zieren J, Steiert A, Jacobi CA, Muller JM. Prognosis factors in carcinoma of the head of the pancreas. *Dig Surg*. 17:29-35 (2000)
- Werk EE, Sholiton LJ, Marnell RT. *Metabolism*. 13: 1425 (1964)
- Whitehouse AS, Tisdale MJ. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. *Br J Cancer*. 89:1116-22 (2003).
- Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC, Fearon KC. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. *Nutrition*. 12:S27-30 (1996)
- Wigmore SJ, Plester CE, Richardson RA and Fearon KCH. Changes in nutritional status associated with unresectable pancreatic cancer. *Br. J. Cancer*. 75: 106-9 (1997a)
- Wigmore SJ, Plester CE, Ross JA and Fearon KCH. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. *Br. J. Surg*. 84: 196-7 (1997b)
- Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ and Fearon KC. Characteristic of patients with pancreatic cancer expressing a novel cancer cachectic factor. *Br. J. Surg*. 87: 53-8 (2000)
- Williams AB, Decourten-Myers GM, Fischer JE, Luo G, Sun X, and Hasselgren PO. Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. *FASEB J* 13:1435-1443, (1999)
- Williamson DH. Determination with alanine dehydrogenase. "Methods of Enzymatic Analysis" (Ed. Bergmeyer, H.U.), pp. 1679-1682 Academic Press, New York (1974)
- Wing SS and Goldberg AL. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. *Am. J. Physiol*. 264: E668-76 (1993)
- Winkelhake JL, Stampfl S and Zimmerman RJ. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in immune tumor models. *Cancer Res*. 47: 3948-53 (1989)
- Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. *EMBO J*. 18:188-97 (1999)
- Wolf RF, Pearlstone DB, Newman E, Heslin MJ, Burt M, Brennan MF. Growth hormone and insulin combine to improve whole body and skeletal proteins kinetics. *Surgery* 112: 248-91 (1992)
- Woods SC, Seeley RJ, Porte D Jr and Schwartz MW. Signals that regulate food intake and energy homeostasis. *Science*. 280: 1378-83 (1998)
- Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IkkappaB kinase-beta: NF-kappaB activation and complex formation with IkkappaB kinase-alpha and NIK. *Science*. 278:866-9 (1997)

**X**

- Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. *Nature*. 366:701-4 (1993)

Xu B, Dube MG, Kalra PS, Farmerie WG, Kaibara A, Moldawer LL, Martin D, Kalra SP. Anorectic effects of the cytokine, ciliary neurotrophic factor, are mediated by hypothalamic neuropeptide Y: comparison with leptin. *Endocrinology*. 139: 466-73 (1998)

Xu Y, Bialik S, Jones BE, Iimuro Y, Kitsis RN, Srinivasan A, Brenner DA, and Czaja MJ. NF-kappaB inactivation converts a hepatocyte cell line TNF-alpha response from proliferation to apoptosis. *Am J Physiol* 275: C1058-66 (1998)

## Y

Yablonka-Reuveni Z, Rudnicki MA, Rivera AJ, Primig M, Anderson JE, Natanson P. The transition from proliferation to differentiation is delayed in satellite cells from mice lacking MyoD. *Dev Biol*. 210:440-55 (1999)

Yaffe, D., Saxel, O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. *Nature* 270: 725-7 (1977)

Yamamoto N, Kawamura I, Nishigaki F, Tsujimoto S, Naoe Y, Inami M, Elisabeth L, Manda T, Shimomura K. Effect of FR143430, a novel cytokine suppressive agent, on adenocarcinoma colon-26-induced cachexia in mice. *Anticancer Res*. 18: 139-44 (1998)

Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ, Israel A. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. *Cell*. 93:1231-40 (1998)

Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X. Prevention of apoptosis by bcl-2, release of cytochrom c from mitochondria blocked. *Science*. 275: 1129-32 (1997)

Yang Q, Bassel-Duby R, Williams RS. Transient expression of a winged-helix protein, MNF-beta, during myogenesis. *Mol Cell Biol*. 17:5236-43 (1997)

Yarden Y, Escobedo JA, Kuang WJ, Yang-Feng TL, Daniel TO, Tremble PM, Chen EY, Ando ME, Harkins RN, Francke U, Fried VA, Ullrich A, Williams LT. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. *Nature* 323: 226-32 (1986)

Yasumoto K, Mukaida N, Harada A, Kuno K, Akiyama M, Nakashima E, Fujioka N, Mai M, Kasahara T, Fujimoto-Ouchi K, et al. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. *Cancer Res*. 55:921-7 (1995)

## Z

Zamir O, Hasselgren PO, James Higashiguchi T, Fischer JE. Effect of tumor necrosis factor of interleukin-1 on muscle amino acid uptake and the role of glucocorticoids. *Surg. Gynecol. Obstet*. 177: 27-32 (1993)

Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. *Cell*. 91:243-52 (1997)

Zentella Z, Manogue K and Cerami A. Cachectin/TNF-mediated lactate production in cultured myocytes is linked to activation of a futile substrate cycle. *Cytokine*. 5: 436-47 (1993)

Zhang W, Behringer RR, Olson EN. Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib anomalies. *Genes Dev*. 9:1388-99 (1995)

Zhao SP, Xie XM. Captopril inhibits the production of tumor necrosis factor-alpha by human mononuclear cells in patients with congestive heart failure. *Clin Chim Acta*. 304:85-90 (2001)

Zhou LZ, Johnson AP, Rando TA. NF kappa B and AP-1 mediate transcriptional responses to oxidative stress in skeletal muscle cells. *Free Radic Biol Med.* 31:1405-16 (2001)

Zhou W, Jiang ZW, Tian J, Jiang J, Li N, Li JS. Role of NF-kappaB and cytokine in experimental cancer cachexia. *World J Gastroenterol.* 9:1567-70 (2003)

Zhu Z, Miller JB. MRF4 can substitute for myogenin during early stages of myogenesis. *Dev Dyn.* 209:233-41 (1997)

Ziegler TR, Young LS, Benfell K, Scheltinga M, Hortos K, Bye R, Morrow FD, Jacobs RJ, Antin JH. Clinical and metabolic efficacy of of glutamin-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. *Ann. Inter. Med.* 116: 821-28 (1992)

Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB and Lippman M. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. *Cancer Res.* 51: 3590-4 (1991)

Zúñiga-Guijardo S, Garfinkel PE and Zinman B. Changes in insulin sensitivity and clearance in anorexia nervosa. *Metabolism* 35: 1096-100 (1986)